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ABSTRACT
Objective: To assess the efficacy of Memantine as a preventive and therapeutic intervention for migraine and 
tension-type headache. Methods: This clinical trial was conducted over a period of 3 months. A total of 44 subjects, 
with diagnosed migraine and/or tension-type headache, presenting to a private neurology clinic in Karachi, Pakistan 
were selected through purposive sampling technique. Patients were treated with incremental doses of Memantine. 
Adult patients belonging to both genders were included in the study. Data was analyzed using SPSS version 16.0 and 
associations were made using Chi square test with p-value of less than 0.05 taken as significant. Results: Out of 44 
patients, 35 (79.5%) were females and 9 (20.5%) were males which shows a very high occurrence of migraine and 
tension-type headache in females. Average age was found to be 32.6 ≈ 33 years. Efficacy of the drug was observed 
to be 81.8% which is significantly high. The baseline MIDAS score when compared with the score at 3-month follow-up 
by applying Wilcoxon signed rank test showed mean ± S.D (39.52±21.27 vs. 6.72±6.41) where p=0.000 (<0.05) 
which shows a highly significant result. All 44 patients were known cases of migraine while 25% (11) of them also 
suffered from tension-type headache. Patients were treated with incremental doses of Memantine and were observed 
for the efficacy of the drug. Patients maintained their diaries of intensity of pain, distressing influence of the pain and 
how it hindered their daily routine. Results showed that intensity of pain decreased significantly by the end of the 3rd 
month of treatment and majority of the patients felt less distressed on their final follow-up visit.  By the end of the 3rd 
month, the level of hindrance in the daily routines of the patients caused by the headache also fell significantly. 
Conclusion: Memantine has significant beneficial effects in reducing intensity of pain and disability in patients with 
migraine and tension type headache.
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O R I G I N A L  A R T I C L E
BACKGROUND
Memantine, an N-methyl D-aspartate (NMDA) receptor 
antagonist, works through its intrinsic blockade of 
afferent signals of pain transmission, known as the 
glutamate system, which plays a major role in 
pathophysiology of tension-type headache (TTH) and 
migraine (1). Memantine works as an uncompetitive, 
voltage-dependent, low affinity, open channel antagonist. 
By binding to the NMDA receptor with a higher affinity 
than Mg2+ ions, Memantine inhibits the prolonged 
influx of Ca2+ ions, which forms the basis of neuronal 
excitotoxicity. Most importantly, its dissociation rate is 
relatively faster which allows it not to accumulate 
substantially in the synaptic channels, hence, it does 
not interfere with the normal synaptic transmission 
(2,3,4,5). Therefore, it can be used as an effective modality 
in prophylaxis and treatment for chronic pain disorders 
including tension-type headache and migraine. During 
the recent decade, Memantine has evolved as a 
revolutionary drug in the treatment of chronic pain 
states. Its efficacy as a neuroprotective drug has been 
demonstrated through various researches (1,6,7). 
Glutamate and other excitatory neurotransmitters have 
been highlighted to be involved in transmission of 
signals to spinal cord or brainstem in chronic pain 
states. Similarly, these neurotransmitters are thought to 
be involved in potentiation and augmentation of the 
pain transmission cascade in chronic headache 
conditions (1). Memantine has also shown potential in 
addressing the issues of complex regional pain 
syndrome and phantom limb pain, which suggests that 
its effectiveness in relieving pain depends on the kind of 
pain under consideration (8). Cognitive problems have 
often been reported by patients with chronic pain 
disorders. Memantine, being a glutamate receptor 
antagonist, has the capacity to tackle both of these 
problems (9). Furthermore, in several clinical trials, 
Memantine has shown very low incidents of adverse 
effects (10,11). Studies have proven that Memantine has 
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its excellent effects on D2 receptors as well, preventing 
its sensitization during a manic attack, hence it can be 
used as drug of choice for bipolar disorder (12). Recent 
works are being done to evaluate its effectiveness  in 
neurocognitive disorders such as Alzheimer’s disease 
(10,11,13). The aforementioned wide variety of uses of 
Memantine in the field of medicine has greatly 
increased the interest of researchers in this 
revolutionary drug. To the best of our knowledge, no 
study has been conducted in our population about the 
use of NMDA antagonists that could be of major interest 
in regards to the pathophysiology and future treatment of 
Migraine, TTH and other chronic pain disorders.
OPERATIONAL DEFINITIONS
MIGRAINE: A primary headache disorder that is benign 
and recurrent, often life-long, and characterized by 
attacks. Attacks include features such as Headaches, 
most often described as pulsating, throbbing, unilateral 
and aggravated by minor movement and routine physical 
activity; typically lasting hours to 2-3 days Nausea, 
photophobia and phonophobia Attack frequency ranges 
from once a week to once a year (14)
TENSION-TYPE HEADACHE: A primary headache 
disorder characterized by tight, band-like headaches 
that occur bilaterally. These headaches may be related 
to stress or associated with musculoskeletal problems 
in the neck. They may last a few hours or persist for 
several days with or without fluctuations.
TABLE 1: Baseline characteristics
MATERIALS AND METHODS
A total of 44 subjects, with diagnosed migraine and/or 
tension-type headache, presenting to Neuro Clinic and 
Care, a private neurology clinic in Karachi, Pakistan 
were selected through purposive sampling technique. 
Data was collected over a period of three months 
between January 2015 and March 2015. 
INCLUSION CRITERIA INCLUDED: Males and females 
aged between 18 and 65 years Diagnosis of Migraine 
using International Headache Society Criteria for Diag-
nosis of Migraine(15) Diagnosis of TTH using Interna-
tional Headache Society Criteria for Diagnosis of TTH(15) 
Signature of Informed Consent Form. In case of females 
of childbearing age, commitment not to become pregnant 
during the entire duration of the study.
EXCLUSION CRITERIA INCLUDED : Patients below the 
age of 18 and above the age of 65. Patients undergoing 
drug treatment for migraine or TTH. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the washout 
period the patient may take, if necessary, analgesics such as 
Tramadol or Acetaminophen. Patients currently taking 
Memantine or having taken Memantine during the 2 
months prior to recruitment. Another Axis I psychiatric 
disorder using Structured Clinical Interview for DSM-
IVAxis I Disorders (SCID-I) that may interfere with adher-
ence to the study protocol (e.g. alcohol and/or 
substance abuse/dependence, schizophrenia, chronic 
delirium, acute depression etc.) Pregnancy or breast-
feeding. Hypersensitivity to the active ingredient, 
Memantine. Medical conditions that require special 
precautions when administering Memantine according 
to the summary of product characteristics: a) epilepsy 
b) circumstances that may cause high urine pH owing 
to Proteus urinary tract infection or renal tubular acido-
sis c) recent myocardial infarction, d) congestive heart 
disease and e) uncontrolled arterial hypertension. 
Clinically significant and active evidence of liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of prescription drugs that 
may cause drug interactions with Memantine: NMDAR 
antagonists (amantadine, ketamine, dextromethor-
phan), L-Dopa, dopamine agonists and cholinergic 
agonists. Use of non-permitted concomitant medica-
tion during the week prior to the recruitment or where 
the patient is expected to require treatment with such 
drugs: antidepressants (duloxetine, venlafaxine, mirtazap-
ine, bupropion, SSRI, etc), analgesics (pregabalin, 
gabapentin, opiates, etc).
Each patient diagnosed to have migraine and/or TTH 
coming to the outpatient department was explained 
about the purpose of the study including the risks and 
benefits of participation in the study. After obtaining 
signed consent, intervention was started. Patients 
received 20 mg of Memantine (2 tablets of 10 mg 
each).
The dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily
Patients kept headache diaries for migraine and TTH, as 
well as pain scores. Patients were followed up initially at 
1st week, 2nd week, then every month for a total of 
three months. On each follow-up visit, pain rating scale 
and MIDAS questionnaire was filled and patients were 
observed for the efficacy of the drug.
TABLE 2: Intensity of pain, frequency of distress and 
interference at baseline and at 3 months follow-up
OUTCOME MEASURES
Improvement in clinical variables. Intensity of pain. It 
will be evaluated using Pain Rating Scale. It is a horizon-
tal line, 10 cm in length, anchored by word descriptors 
at each end (no pain and extreme pain). Level of 
distress caused by the pain. It will be evaluated with 
Pain Rating Scale. It is a horizontal line, 10 cm in 
length, anchored by word descriptors at each end (no 
distress and extreme distress). Interference of pain with 
normal daily activities. It will be evaluated with Pain 
Rating Scale. It is a horizontal line, 10 cm in length, 
anchored by word descriptors at each end (no interfer-
ence and extreme interference). Disability caused by 
the pain. It will be evaluated with the Migraine Disability
Assessment Test (MIDAS). MIDAS is a 5-item questionnaire 
to measure the health status and level of disability 
caused by the pain in patients with headache disorders.
INTERPRETATION: 0-5 – MIDAS Grade I (Little or no 
disability) 6-10 – MIDAS Grade II (Mild disability) 11-20 
– MIDAS Grade III (Moderate disability) ≥ 21 – MIDAS 
Grade IV (Severe disability).
SPSS version 16.0 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤ 0.05 was taken 
as significant.
FIGURE 1: GENDER DISTRIBUTION AMONG SUBJECTS
RESULTS
Out of 44 patients, 35 (79.5%) were females and 9
(20.5%) were males which shows a very high 
occurrence of migraine and tension-type headache in
females (Figure 1). The mean age of the subjects was
found to be 32.6 ≈ 33 years. Our subjects were 
classified according to the type and nature of chronic 
headache. Comprising of migraine alone, migraine 
along with tension-type headache, migraine changing 
to seizures and others, in coherence with other 
studies.16 All 44 patients were known cases of 
migraine while 25% (11) of them also suffered from 
tension-type headache as shown in Table 1. An initial 
daily dose of 5 mg of Memantine was started for 1 week 
with weekly dose increase of 5 mg up to a maximum 
dose of 20 mg per day, as tolerated. Patients were 
asked to maintain a headache diary of intensity of pain, 
distressing influence of the pain and how it hindered 
their daily routine in order to keep an account of 
effectiveness of the drug in every individual. On each 
follow-up visit, pain rating scale and MIDAS 
questionnaire was filled and patients were observed for 
the efficacy of the drug. Efficacy of the drug was found 
to be 81.8% which is significantly high. The baseline 
MIDAS score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (39.52±21.27 vs. 6.72±6.41) where 
p=0.000 (<0.05) which shows a highly significant 
result as shown in Figure 2. Results in Table 2 show that 
intensity of pain decreased significantly by the end of 
the 3rd month of treatment, with only 2.3% of the 
patients complaining of extreme pain at the final 
follow-up at 3 months while 56.8% of the patients 
complained of extreme pain at the initial visit. Majority 
of the patients felt less distressed on their final 
follow-up visit at 3 months.  6.8% of the patients had 
no distress or discomfort at the final follow-up. By the 
end of the 3rd month, the level of hindrance caused by 
the headache in the daily routines of the patients also 
fell significantly, with only 2.3% of the patients 
complaining of extreme interference of pain with normal 
daily activities at the 3-month follow-up. 
Figure 2:
DISCUSSION
This study sought to explain the efficacy of Memantine 
in the treatment of migraine and tension-type 
headache. A number of studies have elucidated that
Memantine, a low-affinity antagonist to NMDA 
glutamate receptors that are thought to be intrinsic to 
pain transmission, is effective in the treatment and 
prophylaxis of migraine and tension-type headache.(1,6,9,16) 
Memantine works by blocking NMDA glutamate 
receptors that are excitatory amino acids and play an 
intrinsic role in pain transmission, long-term 
potentiation and central sensitization. Therefore, 
blockade of NMDA receptors helps in reducing the 
central barrage of afferent signals that may be involved 
in the maintenance of chronic headache states. As in 
other similar researches (1), the participants in our study 
mainly comprised of females (79.5% vs 20.5%), 
proving a worldwide female dominance in incidence of 
migraine and tension-type headache. The ages of our 
patients ranged from 16 to 65 years. It is reasonable to 
expect migraine symptoms to improve as patients get 
older, however, many people continue to have migraine 
attacks in older age and considerable number of people 
with migraine in later life exist in many populations 
worldwide. According to The Migraine Trust, “many 
migraine sufferers contacting The Migraine Trust have 
said that they expected their migraines to get better as 
they got older. Unfortunately this is not the case for 
everyone. There are many people with migraine in their 
60s, 70s, and 80s.(17) Dr. Vincent Martin, professor of 
medicine and co-director of the Headache and Facial 
Pain Program at the University of Cincinnati says 
headaches increase by 50 to 60 percent in women with 
migraine during perimenopausal and menopausal time 
periods.(18) Biqal and Rapoprt, in their study on 
Memantine in the preventive treatment of refractory 
migraine, reported a decrease in headache frequency 
from 21.8 days at baseline to 16.1 days at 3 months (p 
<0.01) as well as a significant reduction in mean 
disability scores at the final follow-up at three months 
which correlates with the results of our study(9). In our 
study, the baseline disability score when compared with 
the score at 3-month follow-up by applying Wilcoxon 
signed rank test showed mean ± S.D (39.52±21.27 
vs. 6.72±6.41) where p=0.000 (<0.005) which 
shows a highly significant result. Similarly, a randomized,
double-blind, placebo-controlled, cross-over trial
demonstrated a significant reduction in intensity of
headache on a 0-10 verbal rating scale(16). In our study, 
the intensity of headache decreased considerably by the 
end of three months with only 2.3% of the patients 
complaining of extreme pain at the final follow-up visit 
at 3 months compared to 56.8% of the patients 
complaining of extreme pain at the initial visit. 
Furthermore, at the final follow-up visit, 2.3% of the 
patients were entirely relieved of the pain. In his 
preliminary open-label study conducted on 30 patients 
with chronic refractory headache disorders, Krusz 
reported a 58% and 52% decrease from the baseline in 
the frequency of migraine and tension-type headache 
respectively at the end of one month, which gives a 
similar proportion as in our study (1). As per patients 
self-reporting in their headache diary, the interference 
of headache with routine work markedly reduced in 
frequency from 59% to 40% (p<0.005). When patients 
reported at 3 months follow-up, there was a significant 
reduction in frequency of occurrence of symptoms, 
statistically proven as 39.52±21.27 vs. 6.72±6.41 
(baseline vs. follow-up). According to a meta-analysis, 
Memantine may be a reasonable option for the 
prevention of primary headache disorders as it lowered 
the frequency and intensity of migraine headaches and 
demonstrated only few adverse effects, which is in 
correlation with our study (19). For Memantine to be 
utilized as an abortive treatment, more evidence in the 
form of randomized, double-blinded, placebo-controlled 
clinical trials comparing Memantine with a standard 
abortive treatment will be needed. In our study, none of 
the patients developed significant adverse effects to 
warrant exclusion from the study. Efficacy of the drug, in 
our study, was observed to be 81.8% at the end of 
three months but more Phase 2 and 3 clinical trials are 
needed before the definitive duration of treatment can
be established. 
CONCLUSION 
Memantine is an effective drug for the prophylactic 
treatment of migraine and tension-type headache in terms 
of reducing intensity of pain and improving the quality of life. 
A randomized, placebo-controlled, double-blind clinical trial is 
needed to confirm our observations.
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BACKGROUND
Memantine, an N-methyl D-aspartate (NMDA) receptor 
antagonist, works through its intrinsic blockade of 
afferent signals of pain transmission, known as the 
glutamate system, which plays a major role in 
pathophysiology of tension-type headache (TTH) and 
migraine (1). Memantine works as an uncompetitive, 
voltage-dependent, low affinity, open channel antagonist. 
By binding to the NMDA receptor with a higher affinity 
than Mg2+ ions, Memantine inhibits the prolonged 
influx of Ca2+ ions, which forms the basis of neuronal 
excitotoxicity. Most importantly, its dissociation rate is 
relatively faster which allows it not to accumulate 
substantially in the synaptic channels, hence, it does 
not interfere with the normal synaptic transmission 
(2,3,4,5). Therefore, it can be used as an effective modality 
in prophylaxis and treatment for chronic pain disorders 
including tension-type headache and migraine. During 
the recent decade, Memantine has evolved as a 
revolutionary drug in the treatment of chronic pain 
states. Its efficacy as a neuroprotective drug has been 
demonstrated through various researches (1,6,7). 
Glutamate and other excitatory neurotransmitters have 
been highlighted to be involved in transmission of 
signals to spinal cord or brainstem in chronic pain 
states. Similarly, these neurotransmitters are thought to 
be involved in potentiation and augmentation of the 
pain transmission cascade in chronic headache 
conditions (1). Memantine has also shown potential in 
addressing the issues of complex regional pain 
syndrome and phantom limb pain, which suggests that 
its effectiveness in relieving pain depends on the kind of 
pain under consideration (8). Cognitive problems have 
often been reported by patients with chronic pain 
disorders. Memantine, being a glutamate receptor 
antagonist, has the capacity to tackle both of these 
problems (9). Furthermore, in several clinical trials, 
Memantine has shown very low incidents of adverse 
effects (10,11). Studies have proven that Memantine has 
its excellent effects on D2 receptors as well, preventing 
its sensitization during a manic attack, hence it can be 
used as drug of choice for bipolar disorder (12). Recent 
works are being done to evaluate its effectiveness  in 
neurocognitive disorders such as Alzheimer’s disease 
(10,11,13). The aforementioned wide variety of uses of 
Memantine in the field of medicine has greatly 
increased the interest of researchers in this 
revolutionary drug. To the best of our knowledge, no 
study has been conducted in our population about the 
use of NMDA antagonists that could be of major interest 
in regards to the pathophysiology and future treatment of 
Migraine, TTH and other chronic pain disorders.
OPERATIONAL DEFINITIONS
MIGRAINE: A primary headache disorder that is benign 
and recurrent, often life-long, and characterized by 
attacks. Attacks include features such as Headaches, 
most often described as pulsating, throbbing, unilateral 
and aggravated by minor movement and routine physical 
activity; typically lasting hours to 2-3 days Nausea, 
photophobia and phonophobia Attack frequency ranges 
from once a week to once a year (14)
TENSION-TYPE HEADACHE: A primary headache 
disorder characterized by tight, band-like headaches 
that occur bilaterally. These headaches may be related 
to stress or associated with musculoskeletal problems 
in the neck. They may last a few hours or persist for 
several days with or without fluctuations.
TABLE 1: Baseline characteristics
MATERIALS AND METHODS
A total of 44 subjects, with diagnosed migraine and/or 
tension-type headache, presenting to Neuro Clinic and 
Care, a private neurology clinic in Karachi, Pakistan 
were selected through purposive sampling technique. 
Data was collected over a period of three months 
between January 2015 and March 2015. 
INCLUSION CRITERIA INCLUDED: Males and females 
aged between 18 and 65 years Diagnosis of Migraine 
using International Headache Society Criteria for Diag-
nosis of Migraine(15) Diagnosis of TTH using Interna-
tional Headache Society Criteria for Diagnosis of TTH(15) 
Signature of Informed Consent Form. In case of females 
of childbearing age, commitment not to become pregnant 
during the entire duration of the study.
EXCLUSION CRITERIA INCLUDED : Patients below the 
age of 18 and above the age of 65. Patients undergoing 
drug treatment for migraine or TTH. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the washout 
period the patient may take, if necessary, analgesics such as 
Tramadol or Acetaminophen. Patients currently taking 
Memantine or having taken Memantine during the 2 
months prior to recruitment. Another Axis I psychiatric 
disorder using Structured Clinical Interview for DSM-
IVAxis I Disorders (SCID-I) that may interfere with adher-
ence to the study protocol (e.g. alcohol and/or 
substance abuse/dependence, schizophrenia, chronic 
delirium, acute depression etc.) Pregnancy or breast-
feeding. Hypersensitivity to the active ingredient, 
Memantine. Medical conditions that require special 
precautions when administering Memantine according 
to the summary of product characteristics: a) epilepsy 
b) circumstances that may cause high urine pH owing 
to Proteus urinary tract infection or renal tubular acido-
sis c) recent myocardial infarction, d) congestive heart 
disease and e) uncontrolled arterial hypertension. 
Clinically significant and active evidence of liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of prescription drugs that 
may cause drug interactions with Memantine: NMDAR 
antagonists (amantadine, ketamine, dextromethor-
phan), L-Dopa, dopamine agonists and cholinergic 
agonists. Use of non-permitted concomitant medica-
tion during the week prior to the recruitment or where 
the patient is expected to require treatment with such 
drugs: antidepressants (duloxetine, venlafaxine, mirtazap-
ine, bupropion, SSRI, etc), analgesics (pregabalin, 
gabapentin, opiates, etc).
Each patient diagnosed to have migraine and/or TTH 
coming to the outpatient department was explained 
about the purpose of the study including the risks and 
benefits of participation in the study. After obtaining 
signed consent, intervention was started. Patients 
received 20 mg of Memantine (2 tablets of 10 mg 
each).
The dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily
Patients kept headache diaries for migraine and TTH, as 
well as pain scores. Patients were followed up initially at 
1st week, 2nd week, then every month for a total of 
three months. On each follow-up visit, pain rating scale 
and MIDAS questionnaire was filled and patients were 
observed for the efficacy of the drug.
TABLE 2: Intensity of pain, frequency of distress and 
interference at baseline and at 3 months follow-up
OUTCOME MEASURES
Improvement in clinical variables. Intensity of pain. It 
will be evaluated using Pain Rating Scale. It is a horizon-
tal line, 10 cm in length, anchored by word descriptors 
at each end (no pain and extreme pain). Level of 
distress caused by the pain. It will be evaluated with 
Pain Rating Scale. It is a horizontal line, 10 cm in 
length, anchored by word descriptors at each end (no 
distress and extreme distress). Interference of pain with 
normal daily activities. It will be evaluated with Pain 
Rating Scale. It is a horizontal line, 10 cm in length, 
anchored by word descriptors at each end (no interfer-
ence and extreme interference). Disability caused by 
the pain. It will be evaluated with the Migraine Disability
Assessment Test (MIDAS). MIDAS is a 5-item questionnaire 
to measure the health status and level of disability 
caused by the pain in patients with headache disorders.
INTERPRETATION: 0-5 – MIDAS Grade I (Little or no 
disability) 6-10 – MIDAS Grade II (Mild disability) 11-20 
– MIDAS Grade III (Moderate disability) ≥ 21 – MIDAS 
Grade IV (Severe disability).
SPSS version 16.0 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤ 0.05 was taken 
as significant.
FIGURE 1: GENDER DISTRIBUTION AMONG SUBJECTS
RESULTS
Out of 44 patients, 35 (79.5%) were females and 9
(20.5%) were males which shows a very high 
occurrence of migraine and tension-type headache in
females (Figure 1). The mean age of the subjects was
found to be 32.6 ≈ 33 years. Our subjects were 
classified according to the type and nature of chronic 
headache. Comprising of migraine alone, migraine 
along with tension-type headache, migraine changing 
to seizures and others, in coherence with other 
studies.16 All 44 patients were known cases of 
migraine while 25% (11) of them also suffered from 
tension-type headache as shown in Table 1. An initial 
daily dose of 5 mg of Memantine was started for 1 week 
with weekly dose increase of 5 mg up to a maximum 
dose of 20 mg per day, as tolerated. Patients were 
asked to maintain a headache diary of intensity of pain, 
distressing influence of the pain and how it hindered 
their daily routine in order to keep an account of 
effectiveness of the drug in every individual. On each 
follow-up visit, pain rating scale and MIDAS 
questionnaire was filled and patients were observed for 
the efficacy of the drug. Efficacy of the drug was found 
to be 81.8% which is significantly high. The baseline 
MIDAS score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (39.52±21.27 vs. 6.72±6.41) where 
p=0.000 (<0.05) which shows a highly significant 
result as shown in Figure 2. Results in Table 2 show that 
intensity of pain decreased significantly by the end of 
the 3rd month of treatment, with only 2.3% of the 
patients complaining of extreme pain at the final 
follow-up at 3 months while 56.8% of the patients 
complained of extreme pain at the initial visit. Majority 
of the patients felt less distressed on their final 
follow-up visit at 3 months.  6.8% of the patients had 
no distress or discomfort at the final follow-up. By the 
end of the 3rd month, the level of hindrance caused by 
the headache in the daily routines of the patients also 
fell significantly, with only 2.3% of the patients 
complaining of extreme interference of pain with normal 
daily activities at the 3-month follow-up. 
Figure 2:
DISCUSSION
This study sought to explain the efficacy of Memantine 
in the treatment of migraine and tension-type 
headache. A number of studies have elucidated that
Memantine, a low-affinity antagonist to NMDA 
glutamate receptors that are thought to be intrinsic to 
pain transmission, is effective in the treatment and 
prophylaxis of migraine and tension-type headache.(1,6,9,16) 
Memantine works by blocking NMDA glutamate 
receptors that are excitatory amino acids and play an 
intrinsic role in pain transmission, long-term 
potentiation and central sensitization. Therefore, 
blockade of NMDA receptors helps in reducing the 
central barrage of afferent signals that may be involved 
in the maintenance of chronic headache states. As in 
other similar researches (1), the participants in our study 
mainly comprised of females (79.5% vs 20.5%), 
proving a worldwide female dominance in incidence of 
migraine and tension-type headache. The ages of our 
patients ranged from 16 to 65 years. It is reasonable to 
expect migraine symptoms to improve as patients get 
older, however, many people continue to have migraine 
attacks in older age and considerable number of people 
with migraine in later life exist in many populations 
worldwide. According to The Migraine Trust, “many 
migraine sufferers contacting The Migraine Trust have 
said that they expected their migraines to get better as 
they got older. Unfortunately this is not the case for 
everyone. There are many people with migraine in their 
60s, 70s, and 80s.(17) Dr. Vincent Martin, professor of 
medicine and co-director of the Headache and Facial 
Pain Program at the University of Cincinnati says 
headaches increase by 50 to 60 percent in women with 
migraine during perimenopausal and menopausal time 
periods.(18) Biqal and Rapoprt, in their study on 
Memantine in the preventive treatment of refractory 
migraine, reported a decrease in headache frequency 
from 21.8 days at baseline to 16.1 days at 3 months (p 
<0.01) as well as a significant reduction in mean 
disability scores at the final follow-up at three months 
which correlates with the results of our study(9). In our 
study, the baseline disability score when compared with 
the score at 3-month follow-up by applying Wilcoxon 
signed rank test showed mean ± S.D (39.52±21.27 
vs. 6.72±6.41) where p=0.000 (<0.005) which 
shows a highly significant result. Similarly, a randomized,
double-blind, placebo-controlled, cross-over trial
demonstrated a significant reduction in intensity of
headache on a 0-10 verbal rating scale(16). In our study, 
the intensity of headache decreased considerably by the 
end of three months with only 2.3% of the patients 
complaining of extreme pain at the final follow-up visit 
at 3 months compared to 56.8% of the patients 
complaining of extreme pain at the initial visit. 
Furthermore, at the final follow-up visit, 2.3% of the 
patients were entirely relieved of the pain. In his 
preliminary open-label study conducted on 30 patients 
with chronic refractory headache disorders, Krusz 
reported a 58% and 52% decrease from the baseline in 
the frequency of migraine and tension-type headache 
respectively at the end of one month, which gives a 
similar proportion as in our study (1). As per patients 
self-reporting in their headache diary, the interference 
of headache with routine work markedly reduced in 
frequency from 59% to 40% (p<0.005). When patients 
reported at 3 months follow-up, there was a significant 
reduction in frequency of occurrence of symptoms, 
statistically proven as 39.52±21.27 vs. 6.72±6.41 
(baseline vs. follow-up). According to a meta-analysis, 
Memantine may be a reasonable option for the 
prevention of primary headache disorders as it lowered 
the frequency and intensity of migraine headaches and 
demonstrated only few adverse effects, which is in 
correlation with our study (19). For Memantine to be 
utilized as an abortive treatment, more evidence in the 
form of randomized, double-blinded, placebo-controlled 
clinical trials comparing Memantine with a standard 
abortive treatment will be needed. In our study, none of 
the patients developed significant adverse effects to 
warrant exclusion from the study. Efficacy of the drug, in 
our study, was observed to be 81.8% at the end of 
three months but more Phase 2 and 3 clinical trials are 
needed before the definitive duration of treatment can
be established. 
CONCLUSION 
Memantine is an effective drug for the prophylactic 
treatment of migraine and tension-type headache in terms 
of reducing intensity of pain and improving the quality of life. 
A randomized, placebo-controlled, double-blind clinical trial is 
needed to confirm our observations.
ACKNOWLEDGEMENTS
We report no conflict of interest and no funding was 
received for this work. We thank the patients and their 
families for giving their consent for publishing this study.
REFERENCES
1.   Krusz JC. Memantine for migraine and tension-type 
     headache Prophylaxis. http://www.practicalpainma- 
      nagement.com/pain/headache/migraine/memantine- 
      migraine-tension-type-headache-prophylaxis. 
     (Date a ccessed: April 2015)
2.   Zinkevich VA, Grafova VN, Kukushkin ML, and 
     Kiselev AV. Effect of akatinol (memantine) in 
     central spinal pain syndrome. Bull Exp Biol Med. 
     May 2000. 129(5): 420-422
3.   Wood PL. The NMDA receptor complex: a long and 
      winding road to therapeutics. Drugs. 2005; 8(3):2 
      29-35
4.   Hewitt DJ. The use of NMDA-receptor antagonists 
      in the treatment of chronic pain. Clin J Pain. 2000; 
      16(2 Suppl):S73-9
5.   Block F, Habermeyer B. Glutamate antagonists for 
     treatment of neuropathic pain. Schmerz. 2003; 
     17(4): 261-7
6    Henry KA. Memantine for the prophylaxis of chronic 
      tension-type headache. Curr Pain Headache Rep. 
      2009; 13(6): 423-4
7.   Lamprecht MR  Morrison Iii B 3rd. A combination 
     therapy of 17ß-estradiol and memantine is more 
     neuroprotective than monotherapies in an organotypic 
     brain slice culture model of traumatic brain injury. 
     J Neurotrauma. 2015. http://www.ncbi.nlm.nih. 
      gov/pub med/25752651 (Date accessed: April 2015)
8.   Recla JM, Sarantopoulos CD. Combined use of 
     Pregabalin and Memantine in Fibromyalgia Syndrome 
      Treatment: A Novel Analgesic and Neuroprotective 
     Strategy? Med Hypotheses. 2009; 73(2): 177-183
9.   Bigal M, Rapoport A, Shefrell F, et al. Memantine 
     in the preventive treatment of refractory migraine. 
     Headache. 2008; 48(9): 1337-42
10. Reisberg B, Doody R, Stöffler A, et al. Memantine 
     in moderate-to-severe Alzheimer’s disease. N Engl 
     J Med. 2003; 348: 1333–1341
11. Tariot PN, Farlow MR, Grossberg GT, et al. 
     Memantine treatment in patients with moderate to 
     severe Alzheimer disease already receiving 
     donepezil: a randomized controlled trial. JAMA. 
     2004; 291: 317–324
12. Serra G, Demontis F, Serra F et al. Memantine: 
     New prospective in bipolar disorder treatment. 
     World J Psychiatry. 2014; 4(4): 80-90
13. Areosa SA, Sherriff F. Memantine for dementia. 
     Cochrane Database Syst Rev. 2003; (3): CD003154
14. Headache Disorders. http://www.who.int/mediace- 
     ntre/factsheets/fs277/en/ (Date accessed: March 
     2015)
15. The International Classification of Headache clas- 
     sification.org/en/ (Date accessed: March 2015)
16. Lindelof K, Bendtsen L. Memantine for prophylaxis 
     of chronic tension-type headache--a double-blind, 
     randomized, crossover clinical trial. Cephalalgia. 
     2009; 29(3): 314-21
17. Managing Migraine in Later Life. http:// www. 
     migrainetrust.org/factsheet-managing-migraine 
     -in-later-life-10896 (Date acce-ssed: March 2015)
18. http://www.webmd.com/menopause/news/20 
     140624/migraines-may-worsen-during-men- 
     -opause (Date accessed: March 2015)
19. Huang L, Bocek M, Jordan JK, et al. 
     Memantine for the prevention of primary 
     headache disorders. Ann Pharmacother. 2014; 
     48(11):1507-11 
INTRODUCTION
Statins are considered safe and effective drugs that are 
prescribed frequently for their lipid lowering capabilities 
to prevent atherosclerosis and coronary vascular 
disease(1). The most common complaint associated with 
statin use and their discontinuation is muscle pain, 
which ranges in severity from myalgia to 
rhabdomyolysis(2,3,4). Presently there is no known 
treatment that can conclusively achieve resolution of 
statin induced myalgia (SIM) and allow continuation of 
the lipid lowering therapy. A few recent studies have 
indicated a possible potentiating effect of vitamin D
deficiency on the development of SIM(5,6) and
improvement in statin tolerance following supplementation 
and normalization of serum vitamin D levels in most 
deficient patients(7,8). The purpose of this study is to 
identify patients with SIM and evaluate their 25 (OH) 
vitamin D levels with the aim of determining the 
presence or absence of an association between the two.
MATERIALS AND METHODS
This study was approved bythe Shifa International Hospi-
talInstitutional Review Board and Ethics Committee. This 
retrospective reviewof the pathology laboratory data-
base was conducted from January 1, 2013 to Decem-
ber 31, 2013 in order to identify patients tested for 
serum 25-hydroxyvitamin D (25(OH) Vitamin D)and 
concurrent Creatin Kinase (CK) levels. This was followed 
by a chart review of the patients to confirm statin use 
and reporting of myalgia at the time of ordering of these 
laboratory investigations. The 25(OH) Vitamin D levels
are determined at our laboratory by Chemiluminescent-
microparticle immunoassay (CIMA) using the ARCHI-
TECT System by Abott laboratory. The normal values of
9.5 up to 55.5ng/ml are used based on a study 
conducted according to the Clinical Laboratory and 
Standards Institute, Protocol C28-A3(9). CK levels were 
determined using ARCHITECT c SYSTEMs and the 
AEROSET System by spectrophotometery. A normal 
range of 30-200U/L for males and 29-168U/L for 
females is used (10). All patients receiving statin therapy 
who had their 25(OH) vitamin D and CK levels checked 
were included in the study. Patientswith diagnosed 
malignancy, chronic liver disease, rheumatoid arthritis 
and sarcoidosis were excluded from this study. 
Statistical analysis was performed using IBM SPSS 
Statistics Data Editor, v21. Categorical variables were 
assessed using the Chi squared test. Association of 
25(OH) Vitamin D with SIM was calculated using 
logistic regression with adjustment for age and CK 
levels. For all statistical tests a p-Value of <0.05 was 
considered significant.
RESULTS
Between January 1, 2013 and December 31, 2013 a 
total of 825 patients (Figure 1) were tested for 25(OH) 
Vitamin D and CK at the SIH pathology laboratory. 243 
of these patients were tested concurrently. We 
identified 54 of these 243 patients to have received 
Statin therapy, 175 did not and the medical records of 
14 were not available for review. Overall 54 patients 
met the study criteria while 5 patients were excluded 
due to their co-morbidities (3 with Rheumatoid Arthritis, 
1 with Non-Hodgkin’s Lymphoma and 1 with Chronic 
Hepatitis B). 49 patients were included for final 
analysis.
Figure 1. Flow Chart of Patient Selection
The 49 patients receiving statins were divided into two 
groups based on presence or absence of 
myalgia.Differences between the two study groups were 
minimal except for age,with the mean ± standard 
deviation (SD), in the SIM and no SIM groupof 58.38 ± 
10.12 and  67.08 ± 10.04 (p = 0.01 ), respectively 
(Table 1).Analysis of the serum 25(OH) Vitamin D also 
revealed little difference between the two groups. The 
mean serum 25(OH) Vitamin D level in the 24 SIM 
patients was 17.93 ± 12.07 compared to 18.99 ± 
15.2 in the 25 no SIM group (p = 0.81). Evaluation of 
the prescribed statin, the dose and patient 
comorbidities also failed to show significance. 
DISCUSSION
Statin associated muscle adverse reports range from 
1% to 5% in controlled clinical trials to 11% to 29% in 
observational cohorts (11).This discrepancy between 
numerous studies may be due to lack of standard 
definitions that can identify statin induced muscle 
problems, making it difficult to assess the true 
percentage of theseadverse effects (11, 12). Our study 
however, showed a higher percentage (49%) of myalgia 
because we only assessed patients that were tested for 
CK instead of a random population of statin users. 
Considerable debate exists regarding the factors 
influencing occurrence of SIM, indicating a 
multifactorial etiology(13). To that effect we took into 
account patient’s age, gender, CK, specific statin used, 
dosage and co-morbiditiesalong with the 25(OH) 
Vitamin D levels.Although our analysis showsa 
significant difference in patient age betweenthe SIM 
and no SIM group (58.38 ± 10.12 and 67.08 ± 
10.04 (p = 0.01)),the mean age was higher in group 
with no myalgia, which is contrary to the effects of 
advancing age onthe development of myalgia(14).
The remaining variables showed no significant 
difference between the two study groups. Similar to the 
concern regarding factors affecting SIM, there is also 
substantial variation in the range of 25(OH) Vitamin D 
levels that are considered normal. While our laboratory 
reports a normal range of 9.5-55.5 ng/ml, the Mayo 
Medical Laboratories adopts <10ng/ml (severe 
deficiency), 10-24ng/ml (mild – moderate deficiency), 
25-80ng/ml (optimal) and >80ng/ml (possible toxicity) 
(15).Several studies have defined vitamin D deficiency 
as circulating levels of less than 80nmol (32ng/ml) 
(16). We report 21(87.5%) patients with low 25(OH) 
vitamin D (<32ng/ml)in the SIM group and 21(84%) in 
the no SIM group with an overall 42(85.71%) patients 
ascertained to be vitamin D deficient. Of these patients 
6(25%) and 9(36%) have severe 25(OH) vitamin 
deficiency (<9.5ng/ml) in the SIM and no SIM group, 
respectively. The current report revealed that the SIM 
group did not have a significantly lower vitamin D level 
Variable Frequency 
(%) 
Mean ± S.D Range(Min/max) 
Gender 
Male 
Female 
 
9 (20.5%) 
35 
(79.5%) 
  
Age 
 
 32.6±10.32 18/65 
Efficacy of Memantine 36 
(81.8%) 
  
Diagnosis 
Migraine 
Migraine + TTH 
Migraine changing to seizures 
Others 
 
20 
(45.45%) 
11 (25%) 
3 (6.81%) 
10 
(22.7%) 
  
MIDAS Variables 
Missed work or school (no. of days) 
 
  
6.81±7.15 
 
0/30 
Productivity at work/school reduced 
by half (no. of days) 
 6.88±5.52 0/20 
Could not perform household 
chores (no. of days) 
 9.97±6.36 0/33 
Productivity reduced by half in 
household work (no. of days) 
 10.52±6.06 3/32 
Missed leisure activities  5.86±4.84 0/20 
Average headache days  14.39±6.41 1/32 
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BACKGROUND
Memantine, an N-methyl D-aspartate (NMDA) receptor 
antagonist, works through its intrinsic blockade of 
afferent signals of pain transmission, known as the 
glutamate system, which plays a major role in 
pathophysiology of tension-type headache (TTH) and 
migraine (1). Memantine works as an uncompetitive, 
voltage-dependent, low affinity, open channel antagonist. 
By binding to the NMDA receptor with a higher affinity 
than Mg2+ ions, Memantine inhibits the prolonged 
influx of Ca2+ ions, which forms the basis of neuronal 
excitotoxicity. Most importantly, its dissociation rate is 
relatively faster which allows it not to accumulate 
substantially in the synaptic channels, hence, it does 
not interfere with the normal synaptic transmission 
(2,3,4,5). Therefore, it can be used as an effective modality 
in prophylaxis and treatment for chronic pain disorders 
including tension-type headache and migraine. During 
the recent decade, Memantine has evolved as a 
revolutionary drug in the treatment of chronic pain 
states. Its efficacy as a neuroprotective drug has been 
demonstrated through various researches (1,6,7). 
Glutamate and other excitatory neurotransmitters have 
been highlighted to be involved in transmission of 
signals to spinal cord or brainstem in chronic pain 
states. Similarly, these neurotransmitters are thought to 
be involved in potentiation and augmentation of the 
pain transmission cascade in chronic headache 
conditions (1). Memantine has also shown potential in 
addressing the issues of complex regional pain 
syndrome and phantom limb pain, which suggests that 
its effectiveness in relieving pain depends on the kind of 
pain under consideration (8). Cognitive problems have 
often been reported by patients with chronic pain 
disorders. Memantine, being a glutamate receptor 
antagonist, has the capacity to tackle both of these 
problems (9). Furthermore, in several clinical trials, 
Memantine has shown very low incidents of adverse 
effects (10,11). Studies have proven that Memantine has 
its excellent effects on D2 receptors as well, preventing 
its sensitization during a manic attack, hence it can be 
used as drug of choice for bipolar disorder (12). Recent 
works are being done to evaluate its effectiveness  in 
neurocognitive disorders such as Alzheimer’s disease 
(10,11,13). The aforementioned wide variety of uses of 
Memantine in the field of medicine has greatly 
increased the interest of researchers in this 
revolutionary drug. To the best of our knowledge, no 
study has been conducted in our population about the 
use of NMDA antagonists that could be of major interest 
in regards to the pathophysiology and future treatment of 
Migraine, TTH and other chronic pain disorders.
OPERATIONAL DEFINITIONS
MIGRAINE: A primary headache disorder that is benign 
and recurrent, often life-long, and characterized by 
attacks. Attacks include features such as Headaches, 
most often described as pulsating, throbbing, unilateral 
and aggravated by minor movement and routine physical 
activity; typically lasting hours to 2-3 days Nausea, 
photophobia and phonophobia Attack frequency ranges 
from once a week to once a year (14)
TENSION-TYPE HEADACHE: A primary headache 
disorder characterized by tight, band-like headaches 
that occur bilaterally. These headaches may be related 
to stress or associated with musculoskeletal problems 
in the neck. They may last a few hours or persist for 
several days with or without fluctuations.
TABLE 1: Baseline characteristics
MATERIALS AND METHODS
A total of 44 subjects, with diagnosed migraine and/or 
tension-type headache, presenting to Neuro Clinic and 
Care, a private neurology clinic in Karachi, Pakistan 
were selected through purposive sampling technique. 
Data was collected over a period of three months 
between January 2015 and March 2015. 
INCLUSION CRITERIA INCLUDED: Males and females 
aged between 18 and 65 years Diagnosis of Migraine 
using International Headache Society Criteria for Diag-
nosis of Migraine(15) Diagnosis of TTH using Interna-
tional Headache Society Criteria for Diagnosis of TTH(15) 
Signature of Informed Consent Form. In case of females 
of childbearing age, commitment not to become pregnant 
during the entire duration of the study.
EXCLUSION CRITERIA INCLUDED : Patients below the 
age of 18 and above the age of 65. Patients undergoing 
drug treatment for migraine or TTH. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the washout 
period the patient may take, if necessary, analgesics such as 
Tramadol or Acetaminophen. Patients currently taking 
Memantine or having taken Memantine during the 2 
months prior to recruitment. Another Axis I psychiatric 
disorder using Structured Clinical Interview for DSM-
IVAxis I Disorders (SCID-I) that may interfere with adher-
ence to the study protocol (e.g. alcohol and/or 
substance abuse/dependence, schizophrenia, chronic 
delirium, acute depression etc.) Pregnancy or breast-
feeding. Hypersensitivity to the active ingredient, 
Memantine. Medical conditions that require special 
precautions when administering Memantine according 
to the summary of product characteristics: a) epilepsy 
b) circumstances that may cause high urine pH owing 
to Proteus urinary tract infection or renal tubular acido-
sis c) recent myocardial infarction, d) congestive heart 
disease and e) uncontrolled arterial hypertension. 
Clinically significant and active evidence of liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of prescription drugs that 
may cause drug interactions with Memantine: NMDAR 
antagonists (amantadine, ketamine, dextromethor-
phan), L-Dopa, dopamine agonists and cholinergic 
agonists. Use of non-permitted concomitant medica-
tion during the week prior to the recruitment or where 
the patient is expected to require treatment with such 
drugs: antidepressants (duloxetine, venlafaxine, mirtazap-
ine, bupropion, SSRI, etc), analgesics (pregabalin, 
gabapentin, opiates, etc).
Each patient diagnosed to have migraine and/or TTH 
coming to the outpatient department was explained 
about the purpose of the study including the risks and 
benefits of participation in the study. After obtaining 
signed consent, intervention was started. Patients 
received 20 mg of Memantine (2 tablets of 10 mg 
each).
The dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily
Patients kept headache diaries for migraine and TTH, as 
well as pain scores. Patients were followed up initially at 
1st week, 2nd week, then every month for a total of 
three months. On each follow-up visit, pain rating scale 
and MIDAS questionnaire was filled and patients were 
observed for the efficacy of the drug.
TABLE 2: Intensity of pain, frequency of distress and 
interference at baseline and at 3 months follow-up
OUTCOME MEASURES
Improvement in clinical variables. Intensity of pain. It 
will be evaluated using Pain Rating Scale. It is a horizon-
tal line, 10 cm in length, anchored by word descriptors 
at each end (no pain and extreme pain). Level of 
distress caused by the pain. It will be evaluated with 
Pain Rating Scale. It is a horizontal line, 10 cm in 
length, anchored by word descriptors at each end (no 
distress and extreme distress). Interference of pain with 
normal daily activities. It will be evaluated with Pain 
Rating Scale. It is a horizontal line, 10 cm in length, 
anchored by word descriptors at each end (no interfer-
ence and extreme interference). Disability caused by 
the pain. It will be evaluated with the Migraine Disability
Assessment Test (MIDAS). MIDAS is a 5-item questionnaire 
to measure the health status and level of disability 
caused by the pain in patients with headache disorders.
INTERPRETATION: 0-5 – MIDAS Grade I (Little or no 
disability) 6-10 – MIDAS Grade II (Mild disability) 11-20 
– MIDAS Grade III (Moderate disability) ≥ 21 – MIDAS 
Grade IV (Severe disability).
SPSS version 16.0 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤ 0.05 was taken 
as significant.
FIGURE 1: GENDER DISTRIBUTION AMONG SUBJECTS
RESULTS
Out of 44 patients, 35 (79.5%) were females and 9
(20.5%) were males which shows a very high 
occurrence of migraine and tension-type headache in
females (Figure 1). The mean age of the subjects was
found to be 32.6 ≈ 33 years. Our subjects were 
classified according to the type and nature of chronic 
headache. Comprising of migraine alone, migraine 
along with tension-type headache, migraine changing 
to seizures and others, in coherence with other 
studies.16 All 44 patients were known cases of 
migraine while 25% (11) of them also suffered from 
tension-type headache as shown in Table 1. An initial 
daily dose of 5 mg of Memantine was started for 1 week 
with weekly dose increase of 5 mg up to a maximum 
dose of 20 mg per day, as tolerated. Patients were 
asked to maintain a headache diary of intensity of pain, 
distressing influence of the pain and how it hindered 
their daily routine in order to keep an account of 
effectiveness of the drug in every individual. On each 
follow-up visit, pain rating scale and MIDAS 
questionnaire was filled and patients were observed for 
the efficacy of the drug. Efficacy of the drug was found 
to be 81.8% which is significantly high. The baseline 
MIDAS score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (39.52±21.27 vs. 6.72±6.41) where 
p=0.000 (<0.05) which shows a highly significant 
result as shown in Figure 2. Results in Table 2 show that 
intensity of pain decreased significantly by the end of 
the 3rd month of treatment, with only 2.3% of the 
patients complaining of extreme pain at the final 
follow-up at 3 months while 56.8% of the patients 
complained of extreme pain at the initial visit. Majority 
of the patients felt less distressed on their final 
follow-up visit at 3 months.  6.8% of the patients had 
no distress or discomfort at the final follow-up. By the 
end of the 3rd month, the level of hindrance caused by 
the headache in the daily routines of the patients also 
fell significantly, with only 2.3% of the patients 
complaining of extreme interference of pain with normal 
daily activities at the 3-month follow-up. 
Figure 2:
DISCUSSION
This study sought to explain the efficacy of Memantine 
in the treatment of migraine and tension-type 
headache. A number of studies have elucidated that
Memantine, a low-affinity antagonist to NMDA 
glutamate receptors that are thought to be intrinsic to 
pain transmission, is effective in the treatment and 
prophylaxis of migraine and tension-type headache.(1,6,9,16) 
Memantine works by blocking NMDA glutamate 
receptors that are excitatory amino acids and play an 
intrinsic role in pain transmission, long-term 
potentiation and central sensitization. Therefore, 
blockade of NMDA receptors helps in reducing the 
central barrage of afferent signals that may be involved 
in the maintenance of chronic headache states. As in 
other similar researches (1), the participants in our study 
mainly comprised of females (79.5% vs 20.5%), 
proving a worldwide female dominance in incidence of 
migraine and tension-type headache. The ages of our 
patients ranged from 16 to 65 years. It is reasonable to 
expect migraine symptoms to improve as patients get 
older, however, many people continue to have migraine 
attacks in older age and considerable number of people 
with migraine in later life exist in many populations 
worldwide. According to The Migraine Trust, “many 
migraine sufferers contacting The Migraine Trust have 
said that they expected their migraines to get better as 
they got older. Unfortunately this is not the case for 
everyone. There are many people with migraine in their 
60s, 70s, and 80s.(17) Dr. Vincent Martin, professor of 
medicine and co-director of the Headache and Facial 
Pain Program at the University of Cincinnati says 
headaches increase by 50 to 60 percent in women with 
migraine during perimenopausal and menopausal time 
periods.(18) Biqal and Rapoprt, in their study on 
Memantine in the preventive treatment of refractory 
migraine, reported a decrease in headache frequency 
from 21.8 days at baseline to 16.1 days at 3 months (p 
<0.01) as well as a significant reduction in mean 
disability scores at the final follow-up at three months 
which correlates with the results of our study(9). In our 
study, the baseline disability score when compared with 
the score at 3-month follow-up by applying Wilcoxon 
signed rank test showed mean ± S.D (39.52±21.27 
vs. 6.72±6.41) where p=0.000 (<0.005) which 
shows a highly significant result. Similarly, a randomized,
double-blind, placebo-controlled, cross-over trial
demonstrated a significant reduction in intensity of
headache on a 0-10 verbal rating scale(16). In our study, 
the intensity of headache decreased considerably by the 
end of three months with only 2.3% of the patients 
complaining of extreme pain at the final follow-up visit 
at 3 months compared to 56.8% of the patients 
complaining of extreme pain at the initial visit. 
Furthermore, at the final follow-up visit, 2.3% of the 
patients were entirely relieved of the pain. In his 
preliminary open-label study conducted on 30 patients 
with chronic refractory headache disorders, Krusz 
reported a 58% and 52% decrease from the baseline in 
the frequency of migraine and tension-type headache 
respectively at the end of one month, which gives a 
similar proportion as in our study (1). As per patients 
self-reporting in their headache diary, the interference 
of headache with routine work markedly reduced in 
frequency from 59% to 40% (p<0.005). When patients 
reported at 3 months follow-up, there was a significant 
reduction in frequency of occurrence of symptoms, 
statistically proven as 39.52±21.27 vs. 6.72±6.41 
(baseline vs. follow-up). According to a meta-analysis, 
Memantine may be a reasonable option for the 
prevention of primary headache disorders as it lowered 
the frequency and intensity of migraine headaches and 
demonstrated only few adverse effects, which is in 
correlation with our study (19). For Memantine to be 
utilized as an abortive treatment, more evidence in the 
form of randomized, double-blinded, placebo-controlled 
clinical trials comparing Memantine with a standard 
abortive treatment will be needed. In our study, none of 
the patients developed significant adverse effects to 
warrant exclusion from the study. Efficacy of the drug, in 
our study, was observed to be 81.8% at the end of 
three months but more Phase 2 and 3 clinical trials are 
needed before the definitive duration of treatment can
be established. 
CONCLUSION 
Memantine is an effective drug for the prophylactic 
treatment of migraine and tension-type headache in terms 
of reducing intensity of pain and improving the quality of life. 
A randomized, placebo-controlled, double-blind clinical trial is 
needed to confirm our observations.
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INTRODUCTION
Statins are considered safe and effective drugs that are 
prescribed frequently for their lipid lowering capabilities 
to prevent atherosclerosis and coronary vascular 
disease(1). The most common complaint associated with 
statin use and their discontinuation is muscle pain, 
which ranges in severity from myalgia to 
rhabdomyolysis(2,3,4). Presently there is no known 
treatment that can conclusively achieve resolution of 
statin induced myalgia (SIM) and allow continuation of 
the lipid lowering therapy. A few recent studies have 
indicated a possible potentiating effect of vitamin D
deficiency on the development of SIM(5,6) and
improvement in statin tolerance following supplementation 
and normalization of serum vitamin D levels in most 
deficient patients(7,8). The purpose of this study is to 
identify patients with SIM and evaluate their 25 (OH) 
vitamin D levels with the aim of determining the 
presence or absence of an association between the two.
MATERIALS AND METHODS
This study was approved bythe Shifa International Hospi-
talInstitutional Review Board and Ethics Committee. This 
retrospective reviewof the pathology laboratory data-
base was conducted from January 1, 2013 to Decem-
ber 31, 2013 in order to identify patients tested for 
serum 25-hydroxyvitamin D (25(OH) Vitamin D)and 
concurrent Creatin Kinase (CK) levels. This was followed 
by a chart review of the patients to confirm statin use 
and reporting of myalgia at the time of ordering of these 
laboratory investigations. The 25(OH) Vitamin D levels
are determined at our laboratory by Chemiluminescent-
microparticle immunoassay (CIMA) using the ARCHI-
TECT System by Abott laboratory. The normal values of
9.5 up to 55.5ng/ml are used based on a study 
conducted according to the Clinical Laboratory and 
Standards Institute, Protocol C28-A3(9). CK levels were 
determined using ARCHITECT c SYSTEMs and the 
AEROSET System by spectrophotometery. A normal 
range of 30-200U/L for males and 29-168U/L for 
females is used (10). All patients receiving statin therapy 
who had their 25(OH) vitamin D and CK levels checked 
were included in the study. Patientswith diagnosed 
malignancy, chronic liver disease, rheumatoid arthritis 
and sarcoidosis were excluded from this study. 
Statistical analysis was performed using IBM SPSS 
Statistics Data Editor, v21. Categorical variables were 
assessed using the Chi squared test. Association of 
25(OH) Vitamin D with SIM was calculated using 
logistic regression with adjustment for age and CK 
levels. For all statistical tests a p-Value of <0.05 was 
considered significant.
RESULTS
Between January 1, 2013 and December 31, 2013 a 
total of 825 patients (Figure 1) were tested for 25(OH) 
Vitamin D and CK at the SIH pathology laboratory. 243 
of these patients were tested concurrently. We 
identified 54 of these 243 patients to have received 
Statin therapy, 175 did not and the medical records of 
14 were not available for review. Overall 54 patients 
met the study criteria while 5 patients were excluded 
due to their co-morbidities (3 with Rheumatoid Arthritis, 
1 with Non-Hodgkin’s Lymphoma and 1 with Chronic 
Hepatitis B). 49 patients were included for final 
analysis.
Figure 1. Flow Chart of Patient Selection
The 49 patients receiving statins were divided into two 
groups based on presence or absence of 
myalgia.Differences between the two study groups were 
minimal except for age,with the mean ± standard 
deviation (SD), in the SIM and no SIM groupof 58.38 ± 
10.12 and  67.08 ± 10.04 (p = 0.01 ), respectively 
(Table 1).Analysis of the serum 25(OH) Vitamin D also 
revealed little difference between the two groups. The 
mean serum 25(OH) Vitamin D level in the 24 SIM 
patients was 17.93 ± 12.07 compared to 18.99 ± 
15.2 in the 25 no SIM group (p = 0.81). Evaluation of 
the prescribed statin, the dose and patient 
comorbidities also failed to show significance. 
DISCUSSION
Statin associated muscle adverse reports range from 
1% to 5% in controlled clinical trials to 11% to 29% in 
observational cohorts (11).This discrepancy between 
numerous studies may be due to lack of standard 
definitions that can identify statin induced muscle 
problems, making it difficult to assess the true 
percentage of theseadverse effects (11, 12). Our study 
however, showed a higher percentage (49%) of myalgia 
because we only assessed patients that were tested for 
CK instead of a random population of statin users. 
Considerable debate exists regarding the factors 
influencing occurrence of SIM, indicating a 
multifactorial etiology(13). To that effect we took into 
account patient’s age, gender, CK, specific statin used, 
dosage and co-morbiditiesalong with the 25(OH) 
Vitamin D levels.Although our analysis showsa 
significant difference in patient age betweenthe SIM 
and no SIM group (58.38 ± 10.12 and 67.08 ± 
10.04 (p = 0.01)),the mean age was higher in group 
with no myalgia, which is contrary to the effects of 
advancing age onthe development of myalgia(14).
The remaining variables showed no significant 
difference between the two study groups. Similar to the 
concern regarding factors affecting SIM, there is also 
substantial variation in the range of 25(OH) Vitamin D 
levels that are considered normal. While our laboratory 
reports a normal range of 9.5-55.5 ng/ml, the Mayo 
Medical Laboratories adopts <10ng/ml (severe 
deficiency), 10-24ng/ml (mild – moderate deficiency), 
25-80ng/ml (optimal) and >80ng/ml (possible toxicity) 
(15).Several studies have defined vitamin D deficiency 
as circulating levels of less than 80nmol (32ng/ml) 
(16). We report 21(87.5%) patients with low 25(OH) 
vitamin D (<32ng/ml)in the SIM group and 21(84%) in 
the no SIM group with an overall 42(85.71%) patients 
ascertained to be vitamin D deficient. Of these patients 
6(25%) and 9(36%) have severe 25(OH) vitamin 
deficiency (<9.5ng/ml) in the SIM and no SIM group, 
respectively. The current report revealed that the SIM 
group did not have a significantly lower vitamin D level 
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Variable At baseline At 3 month 
follow-up 
                  Frequency (%)              
How intense is your pain now? 
No pain 
Mild 
Moderate 
Severe 
Extreme 
 
0                                    1 (2.3) 
0                                    15 (34.1) 
4 (9.1)                            19 (43.2) 
15(34.1)                          8 (18.2)  
25(56.8)                          1 (2.3)  
How intense was your pain on average last week? 
No pain 
Mild 
Moderate 
Severe 
Extreme 
 
0                                     1 (2.3)  
0                                    11 (25)  
13 (29.5)                        18 (40.9) 
15 (34.1)                        13 (29.5) 
16 (36.4)                         1 (2.3)  
How distressing is your pain now? 
No distress 
Mild 
Moderate 
Severe 
Extreme 
 
0                                     3 (6.8)  
2 (4.5)                             14
(31.8) 
6 (13.6)                            20
(45.5) 
25 (56.8)                          6 (13.6)  
11 (25)                             1 (2.3)  
How distressing was your pain on the average last 
week? 
No distress 
Mild 
Moderate 
Severe 
Extreme  
 
0                                     2 (4.5)  
3 (6.8)                            16 (36.4) 
7 (15.9)                          18 (40.9) 
25 (56.8)                         7 (15.9)  
9 (20.5)                           1 (2.3)  
How much does your pain interfere with your 
normal activities? 
No interference 
Mild 
Moderate 
Severe 
Extreme 
 
0                                     2 (4.5)  
1 (2.3)                              22 (50)  
12 (27.3)                          14
(31.8) 
26 (59.1)                          5 (11.4)  
5 (11.4)                            1 (2.3)  
Variables Mean±S.D p-value 
 
Baseline score vs. follow-up 
at 3 months 
 
39.52±21.27 vs. 6.72±6.41 
 
0.000 
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BACKGROUND
Memantine, an N-methyl D-aspartate (NMDA) receptor 
antagonist, works through its intrinsic blockade of 
afferent signals of pain transmission, known as the 
glutamate system, which plays a major role in 
pathophysiology of tension-type headache (TTH) and 
migraine (1). Memantine works as an uncompetitive, 
voltage-dependent, low affinity, open channel antagonist. 
By binding to the NMDA receptor with a higher affinity 
than Mg2+ ions, Memantine inhibits the prolonged 
influx of Ca2+ ions, which forms the basis of neuronal 
excitotoxicity. Most importantly, its dissociation rate is 
relatively faster which allows it not to accumulate 
substantially in the synaptic channels, hence, it does 
not interfere with the normal synaptic transmission 
(2,3,4,5). Therefore, it can be used as an effective modality 
in prophylaxis and treatment for chronic pain disorders 
including tension-type headache and migraine. During 
the recent decade, Memantine has evolved as a 
revolutionary drug in the treatment of chronic pain 
states. Its efficacy as a neuroprotective drug has been 
demonstrated through various researches (1,6,7). 
Glutamate and other excitatory neurotransmitters have 
been highlighted to be involved in transmission of 
signals to spinal cord or brainstem in chronic pain 
states. Similarly, these neurotransmitters are thought to 
be involved in potentiation and augmentation of the 
pain transmission cascade in chronic headache 
conditions (1). Memantine has also shown potential in 
addressing the issues of complex regional pain 
syndrome and phantom limb pain, which suggests that 
its effectiveness in relieving pain depends on the kind of 
pain under consideration (8). Cognitive problems have 
often been reported by patients with chronic pain 
disorders. Memantine, being a glutamate receptor 
antagonist, has the capacity to tackle both of these 
problems (9). Furthermore, in several clinical trials, 
Memantine has shown very low incidents of adverse 
effects (10,11). Studies have proven that Memantine has 
its excellent effects on D2 receptors as well, preventing 
its sensitization during a manic attack, hence it can be 
used as drug of choice for bipolar disorder (12). Recent 
works are being done to evaluate its effectiveness  in 
neurocognitive disorders such as Alzheimer’s disease 
(10,11,13). The aforementioned wide variety of uses of 
Memantine in the field of medicine has greatly 
increased the interest of researchers in this 
revolutionary drug. To the best of our knowledge, no 
study has been conducted in our population about the 
use of NMDA antagonists that could be of major interest 
in regards to the pathophysiology and future treatment of 
Migraine, TTH and other chronic pain disorders.
OPERATIONAL DEFINITIONS
MIGRAINE: A primary headache disorder that is benign 
and recurrent, often life-long, and characterized by 
attacks. Attacks include features such as Headaches, 
most often described as pulsating, throbbing, unilateral 
and aggravated by minor movement and routine physical 
activity; typically lasting hours to 2-3 days Nausea, 
photophobia and phonophobia Attack frequency ranges 
from once a week to once a year (14)
TENSION-TYPE HEADACHE: A primary headache 
disorder characterized by tight, band-like headaches 
that occur bilaterally. These headaches may be related 
to stress or associated with musculoskeletal problems 
in the neck. They may last a few hours or persist for 
several days with or without fluctuations.
TABLE 1: Baseline characteristics
MATERIALS AND METHODS
A total of 44 subjects, with diagnosed migraine and/or 
tension-type headache, presenting to Neuro Clinic and 
Care, a private neurology clinic in Karachi, Pakistan 
were selected through purposive sampling technique. 
Data was collected over a period of three months 
between January 2015 and March 2015. 
INCLUSION CRITERIA INCLUDED: Males and females 
aged between 18 and 65 years Diagnosis of Migraine 
using International Headache Society Criteria for Diag-
nosis of Migraine(15) Diagnosis of TTH using Interna-
tional Headache Society Criteria for Diagnosis of TTH(15) 
Signature of Informed Consent Form. In case of females 
of childbearing age, commitment not to become pregnant 
during the entire duration of the study.
EXCLUSION CRITERIA INCLUDED : Patients below the 
age of 18 and above the age of 65. Patients undergoing 
drug treatment for migraine or TTH. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the washout 
period the patient may take, if necessary, analgesics such as 
Tramadol or Acetaminophen. Patients currently taking 
Memantine or having taken Memantine during the 2 
months prior to recruitment. Another Axis I psychiatric 
disorder using Structured Clinical Interview for DSM-
IVAxis I Disorders (SCID-I) that may interfere with adher-
ence to the study protocol (e.g. alcohol and/or 
substance abuse/dependence, schizophrenia, chronic 
delirium, acute depression etc.) Pregnancy or breast-
feeding. Hypersensitivity to the active ingredient, 
Memantine. Medical conditions that require special 
precautions when administering Memantine according 
to the summary of product characteristics: a) epilepsy 
b) circumstances that may cause high urine pH owing 
to Proteus urinary tract infection or renal tubular acido-
sis c) recent myocardial infarction, d) congestive heart 
disease and e) uncontrolled arterial hypertension. 
Clinically significant and active evidence of liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of prescription drugs that 
may cause drug interactions with Memantine: NMDAR 
antagonists (amantadine, ketamine, dextromethor-
phan), L-Dopa, dopamine agonists and cholinergic 
agonists. Use of non-permitted concomitant medica-
tion during the week prior to the recruitment or where 
the patient is expected to require treatment with such 
drugs: antidepressants (duloxetine, venlafaxine, mirtazap-
ine, bupropion, SSRI, etc), analgesics (pregabalin, 
gabapentin, opiates, etc).
Each patient diagnosed to have migraine and/or TTH 
coming to the outpatient department was explained 
about the purpose of the study including the risks and 
benefits of participation in the study. After obtaining 
signed consent, intervention was started. Patients 
received 20 mg of Memantine (2 tablets of 10 mg 
each).
The dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily
Patients kept headache diaries for migraine and TTH, as 
well as pain scores. Patients were followed up initially at 
1st week, 2nd week, then every month for a total of 
three months. On each follow-up visit, pain rating scale 
and MIDAS questionnaire was filled and patients were 
observed for the efficacy of the drug.
TABLE 2: Intensity of pain, frequency of distress and 
interference at baseline and at 3 months follow-up
OUTCOME MEASURES
Improvement in clinical variables. Intensity of pain. It 
will be evaluated using Pain Rating Scale. It is a horizon-
tal line, 10 cm in length, anchored by word descriptors 
at each end (no pain and extreme pain). Level of 
distress caused by the pain. It will be evaluated with 
Pain Rating Scale. It is a horizontal line, 10 cm in 
length, anchored by word descriptors at each end (no 
distress and extreme distress). Interference of pain with 
normal daily activities. It will be evaluated with Pain 
Rating Scale. It is a horizontal line, 10 cm in length, 
anchored by word descriptors at each end (no interfer-
ence and extreme interference). Disability caused by 
the pain. It will be evaluated with the Migraine Disability
Assessment Test (MIDAS). MIDAS is a 5-item questionnaire 
to measure the health status and level of disability 
caused by the pain in patients with headache disorders.
INTERPRETATION: 0-5 – MIDAS Grade I (Little or no 
disability) 6-10 – MIDAS Grade II (Mild disability) 11-20 
– MIDAS Grade III (Moderate disability) ≥ 21 – MIDAS 
Grade IV (Severe disability).
SPSS version 16.0 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤ 0.05 was taken 
as significant.
FIGURE 1: GENDER DISTRIBUTION AMONG SUBJECTS
RESULTS
Out of 44 patients, 35 (79.5%) were females and 9
(20.5%) were males which shows a very high 
occurrence of migraine and tension-type headache in
females (Figure 1). The mean age of the subjects was
found to be 32.6 ≈ 33 years. Our subjects were 
classified according to the type and nature of chronic 
headache. Comprising of migraine alone, migraine 
along with tension-type headache, migraine changing 
to seizures and others, in coherence with other 
studies.16 All 44 patients were known cases of 
migraine while 25% (11) of them also suffered from 
tension-type headache as shown in Table 1. An initial 
daily dose of 5 mg of Memantine was started for 1 week 
with weekly dose increase of 5 mg up to a maximum 
dose of 20 mg per day, as tolerated. Patients were 
asked to maintain a headache diary of intensity of pain, 
distressing influence of the pain and how it hindered 
their daily routine in order to keep an account of 
effectiveness of the drug in every individual. On each 
follow-up visit, pain rating scale and MIDAS 
questionnaire was filled and patients were observed for 
the efficacy of the drug. Efficacy of the drug was found 
to be 81.8% which is significantly high. The baseline 
MIDAS score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (39.52±21.27 vs. 6.72±6.41) where 
p=0.000 (<0.05) which shows a highly significant 
result as shown in Figure 2. Results in Table 2 show that 
intensity of pain decreased significantly by the end of 
the 3rd month of treatment, with only 2.3% of the 
patients complaining of extreme pain at the final 
follow-up at 3 months while 56.8% of the patients 
complained of extreme pain at the initial visit. Majority 
of the patients felt less distressed on their final 
follow-up visit at 3 months.  6.8% of the patients had 
no distress or discomfort at the final follow-up. By the 
end of the 3rd month, the level of hindrance caused by 
the headache in the daily routines of the patients also 
fell significantly, with only 2.3% of the patients 
complaining of extreme interference of pain with normal 
daily activities at the 3-month follow-up. 
Figure 2:
DISCUSSION
This study sought to explain the efficacy of Memantine 
in the treatment of migraine and tension-type 
headache. A number of studies have elucidated that
Memantine, a low-affinity antagonist to NMDA 
glutamate receptors that are thought to be intrinsic to 
pain transmission, is effective in the treatment and 
prophylaxis of migraine and tension-type headache.(1,6,9,16) 
Memantine works by blocking NMDA glutamate 
receptors that are excitatory amino acids and play an 
intrinsic role in pain transmission, long-term 
potentiation and central sensitization. Therefore, 
blockade of NMDA receptors helps in reducing the 
central barrage of afferent signals that may be involved 
in the maintenance of chronic headache states. As in 
other similar researches (1), the participants in our study 
mainly comprised of females (79.5% vs 20.5%), 
proving a worldwide female dominance in incidence of 
migraine and tension-type headache. The ages of our 
patients ranged from 16 to 65 years. It is reasonable to 
expect migraine symptoms to improve as patients get 
older, however, many people continue to have migraine 
attacks in older age and considerable number of people 
with migraine in later life exist in many populations 
worldwide. According to The Migraine Trust, “many 
migraine sufferers contacting The Migraine Trust have 
said that they expected their migraines to get better as 
they got older. Unfortunately this is not the case for 
everyone. There are many people with migraine in their 
60s, 70s, and 80s.(17) Dr. Vincent Martin, professor of 
medicine and co-director of the Headache and Facial 
Pain Program at the University of Cincinnati says 
headaches increase by 50 to 60 percent in women with 
migraine during perimenopausal and menopausal time 
periods.(18) Biqal and Rapoprt, in their study on 
Memantine in the preventive treatment of refractory 
migraine, reported a decrease in headache frequency 
from 21.8 days at baseline to 16.1 days at 3 months (p 
<0.01) as well as a significant reduction in mean 
disability scores at the final follow-up at three months 
which correlates with the results of our study(9). In our 
study, the baseline disability score when compared with 
the score at 3-month follow-up by applying Wilcoxon 
signed rank test showed mean ± S.D (39.52±21.27 
vs. 6.72±6.41) where p=0.000 (<0.005) which 
shows a highly significant result. Similarly, a randomized,
double-blind, placebo-controlled, cross-over trial
demonstrated a significant reduction in intensity of
headache on a 0-10 verbal rating scale(16). In our study, 
the intensity of headache decreased considerably by the 
end of three months with only 2.3% of the patients 
complaining of extreme pain at the final follow-up visit 
at 3 months compared to 56.8% of the patients 
complaining of extreme pain at the initial visit. 
Furthermore, at the final follow-up visit, 2.3% of the 
patients were entirely relieved of the pain. In his 
preliminary open-label study conducted on 30 patients 
with chronic refractory headache disorders, Krusz 
reported a 58% and 52% decrease from the baseline in 
the frequency of migraine and tension-type headache 
respectively at the end of one month, which gives a 
similar proportion as in our study (1). As per patients 
self-reporting in their headache diary, the interference 
of headache with routine work markedly reduced in 
frequency from 59% to 40% (p<0.005). When patients 
reported at 3 months follow-up, there was a significant 
reduction in frequency of occurrence of symptoms, 
statistically proven as 39.52±21.27 vs. 6.72±6.41 
(baseline vs. follow-up). According to a meta-analysis, 
Memantine may be a reasonable option for the 
prevention of primary headache disorders as it lowered 
the frequency and intensity of migraine headaches and 
demonstrated only few adverse effects, which is in 
correlation with our study (19). For Memantine to be 
utilized as an abortive treatment, more evidence in the 
form of randomized, double-blinded, placebo-controlled 
clinical trials comparing Memantine with a standard 
abortive treatment will be needed. In our study, none of 
the patients developed significant adverse effects to 
warrant exclusion from the study. Efficacy of the drug, in 
our study, was observed to be 81.8% at the end of 
three months but more Phase 2 and 3 clinical trials are 
needed before the definitive duration of treatment can
be established. 
CONCLUSION 
Memantine is an effective drug for the prophylactic 
treatment of migraine and tension-type headache in terms 
of reducing intensity of pain and improving the quality of life. 
A randomized, placebo-controlled, double-blind clinical trial is 
needed to confirm our observations.
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INTRODUCTION
Statins are considered safe and effective drugs that are 
prescribed frequently for their lipid lowering capabilities 
to prevent atherosclerosis and coronary vascular 
disease(1). The most common complaint associated with 
statin use and their discontinuation is muscle pain, 
which ranges in severity from myalgia to 
rhabdomyolysis(2,3,4). Presently there is no known 
treatment that can conclusively achieve resolution of 
statin induced myalgia (SIM) and allow continuation of 
the lipid lowering therapy. A few recent studies have 
indicated a possible potentiating effect of vitamin D
deficiency on the development of SIM(5,6) and
improvement in statin tolerance following supplementation 
and normalization of serum vitamin D levels in most 
deficient patients(7,8). The purpose of this study is to 
identify patients with SIM and evaluate their 25 (OH) 
vitamin D levels with the aim of determining the 
presence or absence of an association between the two.
MATERIALS AND METHODS
This study was approved bythe Shifa International Hospi-
talInstitutional Review Board and Ethics Committee. This 
retrospective reviewof the pathology laboratory data-
base was conducted from January 1, 2013 to Decem-
ber 31, 2013 in order to identify patients tested for 
serum 25-hydroxyvitamin D (25(OH) Vitamin D)and 
concurrent Creatin Kinase (CK) levels. This was followed 
by a chart review of the patients to confirm statin use 
and reporting of myalgia at the time of ordering of these 
laboratory investigations. The 25(OH) Vitamin D levels
are determined at our laboratory by Chemiluminescent-
microparticle immunoassay (CIMA) using the ARCHI-
TECT System by Abott laboratory. The normal values of
9.5 up to 55.5ng/ml are used based on a study 
conducted according to the Clinical Laboratory and 
Standards Institute, Protocol C28-A3(9). CK levels were 
determined using ARCHITECT c SYSTEMs and the 
AEROSET System by spectrophotometery. A normal 
range of 30-200U/L for males and 29-168U/L for 
females is used (10). All patients receiving statin therapy 
who had their 25(OH) vitamin D and CK levels checked 
were included in the study. Patientswith diagnosed 
malignancy, chronic liver disease, rheumatoid arthritis 
and sarcoidosis were excluded from this study. 
Statistical analysis was performed using IBM SPSS 
Statistics Data Editor, v21. Categorical variables were 
assessed using the Chi squared test. Association of 
25(OH) Vitamin D with SIM was calculated using 
logistic regression with adjustment for age and CK 
levels. For all statistical tests a p-Value of <0.05 was 
considered significant.
RESULTS
Between January 1, 2013 and December 31, 2013 a 
total of 825 patients (Figure 1) were tested for 25(OH) 
Vitamin D and CK at the SIH pathology laboratory. 243 
of these patients were tested concurrently. We 
identified 54 of these 243 patients to have received 
Statin therapy, 175 did not and the medical records of 
14 were not available for review. Overall 54 patients 
met the study criteria while 5 patients were excluded 
due to their co-morbidities (3 with Rheumatoid Arthritis, 
1 with Non-Hodgkin’s Lymphoma and 1 with Chronic 
Hepatitis B). 49 patients were included for final 
analysis.
Figure 1. Flow Chart of Patient Selection
The 49 patients receiving statins were divided into two 
groups based on presence or absence of 
myalgia.Differences between the two study groups were 
minimal except for age,with the mean ± standard 
deviation (SD), in the SIM and no SIM groupof 58.38 ± 
10.12 and  67.08 ± 10.04 (p = 0.01 ), respectively 
(Table 1).Analysis of the serum 25(OH) Vitamin D also 
revealed little difference between the two groups. The 
mean serum 25(OH) Vitamin D level in the 24 SIM 
patients was 17.93 ± 12.07 compared to 18.99 ± 
15.2 in the 25 no SIM group (p = 0.81). Evaluation of 
the prescribed statin, the dose and patient 
comorbidities also failed to show significance. 
DISCUSSION
Statin associated muscle adverse reports range from 
1% to 5% in controlled clinical trials to 11% to 29% in 
observational cohorts (11).This discrepancy between 
numerous studies may be due to lack of standard 
definitions that can identify statin induced muscle 
problems, making it difficult to assess the true 
percentage of theseadverse effects (11, 12). Our study 
however, showed a higher percentage (49%) of myalgia 
because we only assessed patients that were tested for 
CK instead of a random population of statin users. 
Considerable debate exists regarding the factors 
influencing occurrence of SIM, indicating a 
multifactorial etiology(13). To that effect we took into 
account patient’s age, gender, CK, specific statin used, 
dosage and co-morbiditiesalong with the 25(OH) 
Vitamin D levels.Although our analysis showsa 
significant difference in patient age betweenthe SIM 
and no SIM group (58.38 ± 10.12 and 67.08 ± 
10.04 (p = 0.01)),the mean age was higher in group 
with no myalgia, which is contrary to the effects of 
advancing age onthe development of myalgia(14).
The remaining variables showed no significant 
difference between the two study groups. Similar to the 
concern regarding factors affecting SIM, there is also 
substantial variation in the range of 25(OH) Vitamin D 
levels that are considered normal. While our laboratory 
reports a normal range of 9.5-55.5 ng/ml, the Mayo 
Medical Laboratories adopts <10ng/ml (severe 
deficiency), 10-24ng/ml (mild – moderate deficiency), 
25-80ng/ml (optimal) and >80ng/ml (possible toxicity) 
(15).Several studies have defined vitamin D deficiency 
as circulating levels of less than 80nmol (32ng/ml) 
(16). We report 21(87.5%) patients with low 25(OH) 
vitamin D (<32ng/ml)in the SIM group and 21(84%) in 
the no SIM group with an overall 42(85.71%) patients 
ascertained to be vitamin D deficient. Of these patients 
6(25%) and 9(36%) have severe 25(OH) vitamin 
deficiency (<9.5ng/ml) in the SIM and no SIM group, 
respectively. The current report revealed that the SIM 
group did not have a significantly lower vitamin D level 
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BACKGROUND
Memantine, an N-methyl D-aspartate (NMDA) receptor 
antagonist, works through its intrinsic blockade of 
afferent signals of pain transmission, known as the 
glutamate system, which plays a major role in 
pathophysiology of tension-type headache (TTH) and 
migraine (1). Memantine works as an uncompetitive, 
voltage-dependent, low affinity, open channel antagonist. 
By binding to the NMDA receptor with a higher affinity 
than Mg2+ ions, Memantine inhibits the prolonged 
influx of Ca2+ ions, which forms the basis of neuronal 
excitotoxicity. Most importantly, its dissociation rate is 
relatively faster which allows it not to accumulate 
substantially in the synaptic channels, hence, it does 
not interfere with the normal synaptic transmission 
(2,3,4,5). Therefore, it can be used as an effective modality 
in prophylaxis and treatment for chronic pain disorders 
including tension-type headache and migraine. During 
the recent decade, Memantine has evolved as a 
revolutionary drug in the treatment of chronic pain 
states. Its efficacy as a neuroprotective drug has been 
demonstrated through various researches (1,6,7). 
Glutamate and other excitatory neurotransmitters have 
been highlighted to be involved in transmission of 
signals to spinal cord or brainstem in chronic pain 
states. Similarly, these neurotransmitters are thought to 
be involved in potentiation and augmentation of the 
pain transmission cascade in chronic headache 
conditions (1). Memantine has also shown potential in 
addressing the issues of complex regional pain 
syndrome and phantom limb pain, which suggests that 
its effectiveness in relieving pain depends on the kind of 
pain under consideration (8). Cognitive problems have 
often been reported by patients with chronic pain 
disorders. Memantine, being a glutamate receptor 
antagonist, has the capacity to tackle both of these 
problems (9). Furthermore, in several clinical trials, 
Memantine has shown very low incidents of adverse 
effects (10,11). Studies have proven that Memantine has 
its excellent effects on D2 receptors as well, preventing 
its sensitization during a manic attack, hence it can be 
used as drug of choice for bipolar disorder (12). Recent 
works are being done to evaluate its effectiveness  in 
neurocognitive disorders such as Alzheimer’s disease 
(10,11,13). The aforementioned wide variety of uses of 
Memantine in the field of medicine has greatly 
increased the interest of researchers in this 
revolutionary drug. To the best of our knowledge, no 
study has been conducted in our population about the 
use of NMDA antagonists that could be of major interest 
in regards to the pathophysiology and future treatment of 
Migraine, TTH and other chronic pain disorders.
OPERATIONAL DEFINITIONS
MIGRAINE: A primary headache disorder that is benign 
and recurrent, often life-long, and characterized by 
attacks. Attacks include features such as Headaches, 
most often described as pulsating, throbbing, unilateral 
and aggravated by minor movement and routine physical 
activity; typically lasting hours to 2-3 days Nausea, 
photophobia and phonophobia Attack frequency ranges 
from once a week to once a year (14)
TENSION-TYPE HEADACHE: A primary headache 
disorder characterized by tight, band-like headaches 
that occur bilaterally. These headaches may be related 
to stress or associated with musculoskeletal problems 
in the neck. They may last a few hours or persist for 
several days with or without fluctuations.
TABLE 1: Baseline characteristics
MATERIALS AND METHODS
A total of 44 subjects, with diagnosed migraine and/or 
tension-type headache, presenting to Neuro Clinic and 
Care, a private neurology clinic in Karachi, Pakistan 
were selected through purposive sampling technique. 
Data was collected over a period of three months 
between January 2015 and March 2015. 
INCLUSION CRITERIA INCLUDED: Males and females 
aged between 18 and 65 years Diagnosis of Migraine 
using International Headache Society Criteria for Diag-
nosis of Migraine(15) Diagnosis of TTH using Interna-
tional Headache Society Criteria for Diagnosis of TTH(15) 
Signature of Informed Consent Form. In case of females 
of childbearing age, commitment not to become pregnant 
during the entire duration of the study.
EXCLUSION CRITERIA INCLUDED : Patients below the 
age of 18 and above the age of 65. Patients undergoing 
drug treatment for migraine or TTH. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the washout 
period the patient may take, if necessary, analgesics such as 
Tramadol or Acetaminophen. Patients currently taking 
Memantine or having taken Memantine during the 2 
months prior to recruitment. Another Axis I psychiatric 
disorder using Structured Clinical Interview for DSM-
IVAxis I Disorders (SCID-I) that may interfere with adher-
ence to the study protocol (e.g. alcohol and/or 
substance abuse/dependence, schizophrenia, chronic 
delirium, acute depression etc.) Pregnancy or breast-
feeding. Hypersensitivity to the active ingredient, 
Memantine. Medical conditions that require special 
precautions when administering Memantine according 
to the summary of product characteristics: a) epilepsy 
b) circumstances that may cause high urine pH owing 
to Proteus urinary tract infection or renal tubular acido-
sis c) recent myocardial infarction, d) congestive heart 
disease and e) uncontrolled arterial hypertension. 
Clinically significant and active evidence of liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of prescription drugs that 
may cause drug interactions with Memantine: NMDAR 
antagonists (amantadine, ketamine, dextromethor-
phan), L-Dopa, dopamine agonists and cholinergic 
agonists. Use of non-permitted concomitant medica-
tion during the week prior to the recruitment or where 
the patient is expected to require treatment with such 
drugs: antidepressants (duloxetine, venlafaxine, mirtazap-
ine, bupropion, SSRI, etc), analgesics (pregabalin, 
gabapentin, opiates, etc).
Each patient diagnosed to have migraine and/or TTH 
coming to the outpatient department was explained 
about the purpose of the study including the risks and 
benefits of participation in the study. After obtaining 
signed consent, intervention was started. Patients 
received 20 mg of Memantine (2 tablets of 10 mg 
each).
The dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily
Patients kept headache diaries for migraine and TTH, as 
well as pain scores. Patients were followed up initially at 
1st week, 2nd week, then every month for a total of 
three months. On each follow-up visit, pain rating scale 
and MIDAS questionnaire was filled and patients were 
observed for the efficacy of the drug.
TABLE 2: Intensity of pain, frequency of distress and 
interference at baseline and at 3 months follow-up
OUTCOME MEASURES
Improvement in clinical variables. Intensity of pain. It 
will be evaluated using Pain Rating Scale. It is a horizon-
tal line, 10 cm in length, anchored by word descriptors 
at each end (no pain and extreme pain). Level of 
distress caused by the pain. It will be evaluated with 
Pain Rating Scale. It is a horizontal line, 10 cm in 
length, anchored by word descriptors at each end (no 
distress and extreme distress). Interference of pain with 
normal daily activities. It will be evaluated with Pain 
Rating Scale. It is a horizontal line, 10 cm in length, 
anchored by word descriptors at each end (no interfer-
ence and extreme interference). Disability caused by 
the pain. It will be evaluated with the Migraine Disability
Assessment Test (MIDAS). MIDAS is a 5-item questionnaire 
to measure the health status and level of disability 
caused by the pain in patients with headache disorders.
INTERPRETATION: 0-5 – MIDAS Grade I (Little or no 
disability) 6-10 – MIDAS Grade II (Mild disability) 11-20 
– MIDAS Grade III (Moderate disability) ≥ 21 – MIDAS 
Grade IV (Severe disability).
SPSS version 16.0 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤ 0.05 was taken 
as significant.
FIGURE 1: GENDER DISTRIBUTION AMONG SUBJECTS
RESULTS
Out of 44 patients, 35 (79.5%) were females and 9
(20.5%) were males which shows a very high 
occurrence of migraine and tension-type headache in
females (Figure 1). The mean age of the subjects was
found to be 32.6 ≈ 33 years. Our subjects were 
classified according to the type and nature of chronic 
headache. Comprising of migraine alone, migraine 
along with tension-type headache, migraine changing 
to seizures and others, in coherence with other 
studies.16 All 44 patients were known cases of 
migraine while 25% (11) of them also suffered from 
tension-type headache as shown in Table 1. An initial 
daily dose of 5 mg of Memantine was started for 1 week 
with weekly dose increase of 5 mg up to a maximum 
dose of 20 mg per day, as tolerated. Patients were 
asked to maintain a headache diary of intensity of pain, 
distressing influence of the pain and how it hindered 
their daily routine in order to keep an account of 
effectiveness of the drug in every individual. On each 
follow-up visit, pain rating scale and MIDAS 
questionnaire was filled and patients were observed for 
the efficacy of the drug. Efficacy of the drug was found 
to be 81.8% which is significantly high. The baseline 
MIDAS score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (39.52±21.27 vs. 6.72±6.41) where 
p=0.000 (<0.05) which shows a highly significant 
result as shown in Figure 2. Results in Table 2 show that 
intensity of pain decreased significantly by the end of 
the 3rd month of treatment, with only 2.3% of the 
patients complaining of extreme pain at the final 
follow-up at 3 months while 56.8% of the patients 
complained of extreme pain at the initial visit. Majority 
of the patients felt less distressed on their final 
follow-up visit at 3 months.  6.8% of the patients had 
no distress or discomfort at the final follow-up. By the 
end of the 3rd month, the level of hindrance caused by 
the headache in the daily routines of the patients also 
fell significantly, with only 2.3% of the patients 
complaining of extreme interference of pain with normal 
daily activities at the 3-month follow-up. 
Figure 2:
DISCUSSION
This study sought to explain the efficacy of Memantine 
in the treatment of migraine and tension-type 
headache. A number of studies have elucidated that
Memantine, a low-affinity antagonist to NMDA 
glutamate receptors that are thought to be intrinsic to 
pain transmission, is effective in the treatment and 
prophylaxis of migraine and tension-type headache.(1,6,9,16) 
Memantine works by blocking NMDA glutamate 
receptors that are excitatory amino acids and play an 
intrinsic role in pain transmission, long-term 
potentiation and central sensitization. Therefore, 
blockade of NMDA receptors helps in reducing the 
central barrage of afferent signals that may be involved 
in the maintenance of chronic headache states. As in 
other similar researches (1), the participants in our study 
mainly comprised of females (79.5% vs 20.5%), 
proving a worldwide female dominance in incidence of 
migraine and tension-type headache. The ages of our 
patients ranged from 16 to 65 years. It is reasonable to 
expect migraine symptoms to improve as patients get 
older, however, many people continue to have migraine 
attacks in older age and considerable number of people 
with migraine in later life exist in many populations 
worldwide. According to The Migraine Trust, “many 
migraine sufferers contacting The Migraine Trust have 
said that they expected their migraines to get better as 
they got older. Unfortunately this is not the case for 
everyone. There are many people with migraine in their 
60s, 70s, and 80s.(17) Dr. Vincent Martin, professor of 
medicine and co-director of the Headache and Facial 
Pain Program at the University of Cincinnati says 
headaches increase by 50 to 60 percent in women with 
migraine during perimenopausal and menopausal time 
periods.(18) Biqal and Rapoprt, in their study on 
Memantine in the preventive treatment of refractory 
migraine, reported a decrease in headache frequency 
from 21.8 days at baseline to 16.1 days at 3 months (p 
<0.01) as well as a significant reduction in mean 
disability scores at the final follow-up at three months 
which correlates with the results of our study(9). In our 
study, the baseline disability score when compared with 
the score at 3-month follow-up by applying Wilcoxon 
signed rank test showed mean ± S.D (39.52±21.27 
vs. 6.72±6.41) where p=0.000 (<0.005) which 
shows a highly significant result. Similarly, a randomized,
double-blind, placebo-controlled, cross-over trial
demonstrated a significant reduction in intensity of
headache on a 0-10 verbal rating scale(16). In our study, 
the intensity of headache decreased considerably by the 
end of three months with only 2.3% of the patients 
complaining of extreme pain at the final follow-up visit 
at 3 months compared to 56.8% of the patients 
complaining of extreme pain at the initial visit. 
Furthermore, at the final follow-up visit, 2.3% of the 
patients were entirely relieved of the pain. In his 
preliminary open-label study conducted on 30 patients 
with chronic refractory headache disorders, Krusz 
reported a 58% and 52% decrease from the baseline in 
the frequency of migraine and tension-type headache 
respectively at the end of one month, which gives a 
similar proportion as in our study (1). As per patients 
self-reporting in their headache diary, the interference 
of headache with routine work markedly reduced in 
frequency from 59% to 40% (p<0.005). When patients 
reported at 3 months follow-up, there was a significant 
reduction in frequency of occurrence of symptoms, 
statistically proven as 39.52±21.27 vs. 6.72±6.41 
(baseline vs. follow-up). According to a meta-analysis, 
Memantine may be a reasonable option for the 
prevention of primary headache disorders as it lowered 
the frequency and intensity of migraine headaches and 
demonstrated only few adverse effects, which is in 
correlation with our study (19). For Memantine to be 
utilized as an abortive treatment, more evidence in the 
form of randomized, double-blinded, placebo-controlled 
clinical trials comparing Memantine with a standard 
abortive treatment will be needed. In our study, none of 
the patients developed significant adverse effects to 
warrant exclusion from the study. Efficacy of the drug, in 
our study, was observed to be 81.8% at the end of 
three months but more Phase 2 and 3 clinical trials are 
needed before the definitive duration of treatment can
be established. 
CONCLUSION 
Memantine is an effective drug for the prophylactic 
treatment of migraine and tension-type headache in terms 
of reducing intensity of pain and improving the quality of life. 
A randomized, placebo-controlled, double-blind clinical trial is 
needed to confirm our observations.
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INTRODUCTION
Statins are considered safe and effective drugs that are 
prescribed frequently for their lipid lowering capabilities 
to prevent atherosclerosis and coronary vascular 
disease(1). The most common complaint associated with 
statin use and their discontinuation is muscle pain, 
which ranges in severity from myalgia to 
rhabdomyolysis(2,3,4). Presently there is no known 
treatment that can conclusively achieve resolution of 
statin induced myalgia (SIM) and allow continuation of 
the lipid lowering therapy. A few recent studies have 
indicated a possible potentiating effect of vitamin D
deficiency on the development of SIM(5,6) and
improvement in statin tolerance following supplementation 
and normalization of serum vitamin D levels in most 
deficient patients(7,8). The purpose of this study is to 
identify patients with SIM and evaluate their 25 (OH) 
vitamin D levels with the aim of determining the 
presence or absence of an association between the two.
MATERIALS AND METHODS
This study was approved bythe Shifa International Hospi-
talInstitutional Review Board and Ethics Committee. This 
retrospective reviewof the pathology laboratory data-
base was conducted from January 1, 2013 to Decem-
ber 31, 2013 in order to identify patients tested for 
serum 25-hydroxyvitamin D (25(OH) Vitamin D)and 
concurrent Creatin Kinase (CK) levels. This was followed 
by a chart review of the patients to confirm statin use 
and reporting of myalgia at the time of ordering of these 
laboratory investigations. The 25(OH) Vitamin D levels
are determined at our laboratory by Chemiluminescent-
microparticle immunoassay (CIMA) using the ARCHI-
TECT System by Abott laboratory. The normal values of
9.5 up to 55.5ng/ml are used based on a study 
conducted according to the Clinical Laboratory and 
Standards Institute, Protocol C28-A3(9). CK levels were 
determined using ARCHITECT c SYSTEMs and the 
AEROSET System by spectrophotometery. A normal 
range of 30-200U/L for males and 29-168U/L for 
females is used (10). All patients receiving statin therapy 
who had their 25(OH) vitamin D and CK levels checked 
were included in the study. Patientswith diagnosed 
malignancy, chronic liver disease, rheumatoid arthritis 
and sarcoidosis were excluded from this study. 
Statistical analysis was performed using IBM SPSS 
Statistics Data Editor, v21. Categorical variables were 
assessed using the Chi squared test. Association of 
25(OH) Vitamin D with SIM was calculated using 
logistic regression with adjustment for age and CK 
levels. For all statistical tests a p-Value of <0.05 was 
considered significant.
RESULTS
Between January 1, 2013 and December 31, 2013 a 
total of 825 patients (Figure 1) were tested for 25(OH) 
Vitamin D and CK at the SIH pathology laboratory. 243 
of these patients were tested concurrently. We 
identified 54 of these 243 patients to have received 
Statin therapy, 175 did not and the medical records of 
14 were not available for review. Overall 54 patients 
met the study criteria while 5 patients were excluded 
due to their co-morbidities (3 with Rheumatoid Arthritis, 
1 with Non-Hodgkin’s Lymphoma and 1 with Chronic 
Hepatitis B). 49 patients were included for final 
analysis.
Figure 1. Flow Chart of Patient Selection
The 49 patients receiving statins were divided into two 
groups based on presence or absence of 
myalgia.Differences between the two study groups were 
minimal except for age,with the mean ± standard 
deviation (SD), in the SIM and no SIM groupof 58.38 ± 
10.12 and  67.08 ± 10.04 (p = 0.01 ), respectively 
(Table 1).Analysis of the serum 25(OH) Vitamin D also 
revealed little difference between the two groups. The 
mean serum 25(OH) Vitamin D level in the 24 SIM 
patients was 17.93 ± 12.07 compared to 18.99 ± 
15.2 in the 25 no SIM group (p = 0.81). Evaluation of 
the prescribed statin, the dose and patient 
comorbidities also failed to show significance. 
DISCUSSION
Statin associated muscle adverse reports range from 
1% to 5% in controlled clinical trials to 11% to 29% in 
observational cohorts (11).This discrepancy between 
numerous studies may be due to lack of standard 
definitions that can identify statin induced muscle 
problems, making it difficult to assess the true 
percentage of theseadverse effects (11, 12). Our study 
however, showed a higher percentage (49%) of myalgia 
because we only assessed patients that were tested for 
CK instead of a random population of statin users. 
Considerable debate exists regarding the factors 
influencing occurrence of SIM, indicating a 
multifactorial etiology(13). To that effect we took into 
account patient’s age, gender, CK, specific statin used, 
dosage and co-morbiditiesalong with the 25(OH) 
Vitamin D levels.Although our analysis showsa 
significant difference in patient age betweenthe SIM 
and no SIM group (58.38 ± 10.12 and 67.08 ± 
10.04 (p = 0.01)),the mean age was higher in group 
with no myalgia, which is contrary to the effects of 
advancing age onthe development of myalgia(14).
The remaining variables showed no significant 
difference between the two study groups. Similar to the 
concern regarding factors affecting SIM, there is also 
substantial variation in the range of 25(OH) Vitamin D 
levels that are considered normal. While our laboratory 
reports a normal range of 9.5-55.5 ng/ml, the Mayo 
Medical Laboratories adopts <10ng/ml (severe 
deficiency), 10-24ng/ml (mild – moderate deficiency), 
25-80ng/ml (optimal) and >80ng/ml (possible toxicity) 
(15).Several studies have defined vitamin D deficiency 
as circulating levels of less than 80nmol (32ng/ml) 
(16). We report 21(87.5%) patients with low 25(OH) 
vitamin D (<32ng/ml)in the SIM group and 21(84%) in 
the no SIM group with an overall 42(85.71%) patients 
ascertained to be vitamin D deficient. Of these patients 
6(25%) and 9(36%) have severe 25(OH) vitamin 
deficiency (<9.5ng/ml) in the SIM and no SIM group, 
respectively. The current report revealed that the SIM 
group did not have a significantly lower vitamin D level 
1 7 V O L .  1 0  ( 2 )  A P R   -   J U N   2 0 1 5P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
BACKGROUND
Memantine, an N-methyl D-aspartate (NMDA) receptor 
antagonist, works through its intrinsic blockade of 
afferent signals of pain transmission, known as the 
glutamate system, which plays a major role in 
pathophysiology of tension-type headache (TTH) and 
migraine (1). Memantine works as an uncompetitive, 
voltage-dependent, low affinity, open channel antagonist. 
By binding to the NMDA receptor with a higher affinity 
than Mg2+ ions, Memantine inhibits the prolonged 
influx of Ca2+ ions, which forms the basis of neuronal 
excitotoxicity. Most importantly, its dissociation rate is 
relatively faster which allows it not to accumulate 
substantially in the synaptic channels, hence, it does 
not interfere with the normal synaptic transmission 
(2,3,4,5). Therefore, it can be used as an effective modality 
in prophylaxis and treatment for chronic pain disorders 
including tension-type headache and migraine. During 
the recent decade, Memantine has evolved as a 
revolutionary drug in the treatment of chronic pain 
states. Its efficacy as a neuroprotective drug has been 
demonstrated through various researches (1,6,7). 
Glutamate and other excitatory neurotransmitters have 
been highlighted to be involved in transmission of 
signals to spinal cord or brainstem in chronic pain 
states. Similarly, these neurotransmitters are thought to 
be involved in potentiation and augmentation of the 
pain transmission cascade in chronic headache 
conditions (1). Memantine has also shown potential in 
addressing the issues of complex regional pain 
syndrome and phantom limb pain, which suggests that 
its effectiveness in relieving pain depends on the kind of 
pain under consideration (8). Cognitive problems have 
often been reported by patients with chronic pain 
disorders. Memantine, being a glutamate receptor 
antagonist, has the capacity to tackle both of these 
problems (9). Furthermore, in several clinical trials, 
Memantine has shown very low incidents of adverse 
effects (10,11). Studies have proven that Memantine has 
its excellent effects on D2 receptors as well, preventing 
its sensitization during a manic attack, hence it can be 
used as drug of choice for bipolar disorder (12). Recent 
works are being done to evaluate its effectiveness  in 
neurocognitive disorders such as Alzheimer’s disease 
(10,11,13). The aforementioned wide variety of uses of 
Memantine in the field of medicine has greatly 
increased the interest of researchers in this 
revolutionary drug. To the best of our knowledge, no 
study has been conducted in our population about the 
use of NMDA antagonists that could be of major interest 
in regards to the pathophysiology and future treatment of 
Migraine, TTH and other chronic pain disorders.
OPERATIONAL DEFINITIONS
MIGRAINE: A primary headache disorder that is benign 
and recurrent, often life-long, and characterized by 
attacks. Attacks include features such as Headaches, 
most often described as pulsating, throbbing, unilateral 
and aggravated by minor movement and routine physical 
activity; typically lasting hours to 2-3 days Nausea, 
photophobia and phonophobia Attack frequency ranges 
from once a week to once a year (14)
TENSION-TYPE HEADACHE: A primary headache 
disorder characterized by tight, band-like headaches 
that occur bilaterally. These headaches may be related 
to stress or associated with musculoskeletal problems 
in the neck. They may last a few hours or persist for 
several days with or without fluctuations.
TABLE 1: Baseline characteristics
MATERIALS AND METHODS
A total of 44 subjects, with diagnosed migraine and/or 
tension-type headache, presenting to Neuro Clinic and 
Care, a private neurology clinic in Karachi, Pakistan 
were selected through purposive sampling technique. 
Data was collected over a period of three months 
between January 2015 and March 2015. 
INCLUSION CRITERIA INCLUDED: Males and females 
aged between 18 and 65 years Diagnosis of Migraine 
using International Headache Society Criteria for Diag-
nosis of Migraine(15) Diagnosis of TTH using Interna-
tional Headache Society Criteria for Diagnosis of TTH(15) 
Signature of Informed Consent Form. In case of females 
of childbearing age, commitment not to become pregnant 
during the entire duration of the study.
EXCLUSION CRITERIA INCLUDED : Patients below the 
age of 18 and above the age of 65. Patients undergoing 
drug treatment for migraine or TTH. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the washout 
period the patient may take, if necessary, analgesics such as 
Tramadol or Acetaminophen. Patients currently taking 
Memantine or having taken Memantine during the 2 
months prior to recruitment. Another Axis I psychiatric 
disorder using Structured Clinical Interview for DSM-
IVAxis I Disorders (SCID-I) that may interfere with adher-
ence to the study protocol (e.g. alcohol and/or 
substance abuse/dependence, schizophrenia, chronic 
delirium, acute depression etc.) Pregnancy or breast-
feeding. Hypersensitivity to the active ingredient, 
Memantine. Medical conditions that require special 
precautions when administering Memantine according 
to the summary of product characteristics: a) epilepsy 
b) circumstances that may cause high urine pH owing 
to Proteus urinary tract infection or renal tubular acido-
sis c) recent myocardial infarction, d) congestive heart 
disease and e) uncontrolled arterial hypertension. 
Clinically significant and active evidence of liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of prescription drugs that 
may cause drug interactions with Memantine: NMDAR 
antagonists (amantadine, ketamine, dextromethor-
phan), L-Dopa, dopamine agonists and cholinergic 
agonists. Use of non-permitted concomitant medica-
tion during the week prior to the recruitment or where 
the patient is expected to require treatment with such 
drugs: antidepressants (duloxetine, venlafaxine, mirtazap-
ine, bupropion, SSRI, etc), analgesics (pregabalin, 
gabapentin, opiates, etc).
Each patient diagnosed to have migraine and/or TTH 
coming to the outpatient department was explained 
about the purpose of the study including the risks and 
benefits of participation in the study. After obtaining 
signed consent, intervention was started. Patients 
received 20 mg of Memantine (2 tablets of 10 mg 
each).
The dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily
Patients kept headache diaries for migraine and TTH, as 
well as pain scores. Patients were followed up initially at 
1st week, 2nd week, then every month for a total of 
three months. On each follow-up visit, pain rating scale 
and MIDAS questionnaire was filled and patients were 
observed for the efficacy of the drug.
TABLE 2: Intensity of pain, frequency of distress and 
interference at baseline and at 3 months follow-up
OUTCOME MEASURES
Improvement in clinical variables. Intensity of pain. It 
will be evaluated using Pain Rating Scale. It is a horizon-
tal line, 10 cm in length, anchored by word descriptors 
at each end (no pain and extreme pain). Level of 
distress caused by the pain. It will be evaluated with 
Pain Rating Scale. It is a horizontal line, 10 cm in 
length, anchored by word descriptors at each end (no 
distress and extreme distress). Interference of pain with 
normal daily activities. It will be evaluated with Pain 
Rating Scale. It is a horizontal line, 10 cm in length, 
anchored by word descriptors at each end (no interfer-
ence and extreme interference). Disability caused by 
the pain. It will be evaluated with the Migraine Disability
Assessment Test (MIDAS). MIDAS is a 5-item questionnaire 
to measure the health status and level of disability 
caused by the pain in patients with headache disorders.
INTERPRETATION: 0-5 – MIDAS Grade I (Little or no 
disability) 6-10 – MIDAS Grade II (Mild disability) 11-20 
– MIDAS Grade III (Moderate disability) ≥ 21 – MIDAS 
Grade IV (Severe disability).
SPSS version 16.0 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤ 0.05 was taken 
as significant.
FIGURE 1: GENDER DISTRIBUTION AMONG SUBJECTS
RESULTS
Out of 44 patients, 35 (79.5%) were females and 9
(20.5%) were males which shows a very high 
occurrence of migraine and tension-type headache in
females (Figure 1). The mean age of the subjects was
found to be 32.6 ≈ 33 years. Our subjects were 
classified according to the type and nature of chronic 
headache. Comprising of migraine alone, migraine 
along with tension-type headache, migraine changing 
to seizures and others, in coherence with other 
studies.16 All 44 patients were known cases of 
migraine while 25% (11) of them also suffered from 
tension-type headache as shown in Table 1. An initial 
daily dose of 5 mg of Memantine was started for 1 week 
with weekly dose increase of 5 mg up to a maximum 
dose of 20 mg per day, as tolerated. Patients were 
asked to maintain a headache diary of intensity of pain, 
distressing influence of the pain and how it hindered 
their daily routine in order to keep an account of 
effectiveness of the drug in every individual. On each 
follow-up visit, pain rating scale and MIDAS 
questionnaire was filled and patients were observed for 
the efficacy of the drug. Efficacy of the drug was found 
to be 81.8% which is significantly high. The baseline 
MIDAS score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (39.52±21.27 vs. 6.72±6.41) where 
p=0.000 (<0.05) which shows a highly significant 
result as shown in Figure 2. Results in Table 2 show that 
intensity of pain decreased significantly by the end of 
the 3rd month of treatment, with only 2.3% of the 
patients complaining of extreme pain at the final 
follow-up at 3 months while 56.8% of the patients 
complained of extreme pain at the initial visit. Majority 
of the patients felt less distressed on their final 
follow-up visit at 3 months.  6.8% of the patients had 
no distress or discomfort at the final follow-up. By the 
end of the 3rd month, the level of hindrance caused by 
the headache in the daily routines of the patients also 
fell significantly, with only 2.3% of the patients 
complaining of extreme interference of pain with normal 
daily activities at the 3-month follow-up. 
Figure 2:
DISCUSSION
This study sought to explain the efficacy of Memantine 
in the treatment of migraine and tension-type 
headache. A number of studies have elucidated that
Memantine, a low-affinity antagonist to NMDA 
glutamate receptors that are thought to be intrinsic to 
pain transmission, is effective in the treatment and 
prophylaxis of migraine and tension-type headache.(1,6,9,16) 
Memantine works by blocking NMDA glutamate 
receptors that are excitatory amino acids and play an 
intrinsic role in pain transmission, long-term 
potentiation and central sensitization. Therefore, 
blockade of NMDA receptors helps in reducing the 
central barrage of afferent signals that may be involved 
in the maintenance of chronic headache states. As in 
other similar researches (1), the participants in our study 
mainly comprised of females (79.5% vs 20.5%), 
proving a worldwide female dominance in incidence of 
migraine and tension-type headache. The ages of our 
patients ranged from 16 to 65 years. It is reasonable to 
expect migraine symptoms to improve as patients get 
older, however, many people continue to have migraine 
attacks in older age and considerable number of people 
with migraine in later life exist in many populations 
worldwide. According to The Migraine Trust, “many 
migraine sufferers contacting The Migraine Trust have 
said that they expected their migraines to get better as 
they got older. Unfortunately this is not the case for 
everyone. There are many people with migraine in their 
60s, 70s, and 80s.(17) Dr. Vincent Martin, professor of 
medicine and co-director of the Headache and Facial 
Pain Program at the University of Cincinnati says 
headaches increase by 50 to 60 percent in women with 
migraine during perimenopausal and menopausal time 
periods.(18) Biqal and Rapoprt, in their study on 
Memantine in the preventive treatment of refractory 
migraine, reported a decrease in headache frequency 
from 21.8 days at baseline to 16.1 days at 3 months (p 
<0.01) as well as a significant reduction in mean 
disability scores at the final follow-up at three months 
which correlates with the results of our study(9). In our 
study, the baseline disability score when compared with 
the score at 3-month follow-up by applying Wilcoxon 
signed rank test showed mean ± S.D (39.52±21.27 
vs. 6.72±6.41) where p=0.000 (<0.005) which 
shows a highly significant result. Similarly, a randomized,
double-blind, placebo-controlled, cross-over trial
demonstrated a significant reduction in intensity of
headache on a 0-10 verbal rating scale(16). In our study, 
the intensity of headache decreased considerably by the 
end of three months with only 2.3% of the patients 
complaining of extreme pain at the final follow-up visit 
at 3 months compared to 56.8% of the patients 
complaining of extreme pain at the initial visit. 
Furthermore, at the final follow-up visit, 2.3% of the 
patients were entirely relieved of the pain. In his 
preliminary open-label study conducted on 30 patients 
with chronic refractory headache disorders, Krusz 
reported a 58% and 52% decrease from the baseline in 
the frequency of migraine and tension-type headache 
respectively at the end of one month, which gives a 
similar proportion as in our study (1). As per patients 
self-reporting in their headache diary, the interference 
of headache with routine work markedly reduced in 
frequency from 59% to 40% (p<0.005). When patients 
reported at 3 months follow-up, there was a significant 
reduction in frequency of occurrence of symptoms, 
statistically proven as 39.52±21.27 vs. 6.72±6.41 
(baseline vs. follow-up). According to a meta-analysis, 
Memantine may be a reasonable option for the 
prevention of primary headache disorders as it lowered 
the frequency and intensity of migraine headaches and 
demonstrated only few adverse effects, which is in 
correlation with our study (19). For Memantine to be 
utilized as an abortive treatment, more evidence in the 
form of randomized, double-blinded, placebo-controlled 
clinical trials comparing Memantine with a standard 
abortive treatment will be needed. In our study, none of 
the patients developed significant adverse effects to 
warrant exclusion from the study. Efficacy of the drug, in 
our study, was observed to be 81.8% at the end of 
three months but more Phase 2 and 3 clinical trials are 
needed before the definitive duration of treatment can
be established. 
CONCLUSION 
Memantine is an effective drug for the prophylactic 
treatment of migraine and tension-type headache in terms 
of reducing intensity of pain and improving the quality of life. 
A randomized, placebo-controlled, double-blind clinical trial is 
needed to confirm our observations.
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INTRODUCTION
Statins are considered safe and effective drugs that are 
prescribed frequently for their lipid lowering capabilities 
to prevent atherosclerosis and coronary vascular 
disease(1). The most common complaint associated with 
statin use and their discontinuation is muscle pain, 
which ranges in severity from myalgia to 
rhabdomyolysis(2,3,4). Presently there is no known 
treatment that can conclusively achieve resolution of 
statin induced myalgia (SIM) and allow continuation of 
the lipid lowering therapy. A few recent studies have 
indicated a possible potentiating effect of vitamin D
deficiency on the development of SIM(5,6) and
improvement in statin tolerance following supplementation 
and normalization of serum vitamin D levels in most 
deficient patients(7,8). The purpose of this study is to 
identify patients with SIM and evaluate their 25 (OH) 
vitamin D levels with the aim of determining the 
presence or absence of an association between the two.
MATERIALS AND METHODS
This study was approved bythe Shifa International Hospi-
talInstitutional Review Board and Ethics Committee. This 
retrospective reviewof the pathology laboratory data-
base was conducted from January 1, 2013 to Decem-
ber 31, 2013 in order to identify patients tested for 
serum 25-hydroxyvitamin D (25(OH) Vitamin D)and 
concurrent Creatin Kinase (CK) levels. This was followed 
by a chart review of the patients to confirm statin use 
and reporting of myalgia at the time of ordering of these 
laboratory investigations. The 25(OH) Vitamin D levels
are determined at our laboratory by Chemiluminescent-
microparticle immunoassay (CIMA) using the ARCHI-
TECT System by Abott laboratory. The normal values of
9.5 up to 55.5ng/ml are used based on a study 
conducted according to the Clinical Laboratory and 
Standards Institute, Protocol C28-A3(9). CK levels were 
determined using ARCHITECT c SYSTEMs and the 
AEROSET System by spectrophotometery. A normal 
range of 30-200U/L for males and 29-168U/L for 
females is used (10). All patients receiving statin therapy 
who had their 25(OH) vitamin D and CK levels checked 
were included in the study. Patientswith diagnosed 
malignancy, chronic liver disease, rheumatoid arthritis 
and sarcoidosis were excluded from this study. 
Statistical analysis was performed using IBM SPSS 
Statistics Data Editor, v21. Categorical variables were 
assessed using the Chi squared test. Association of 
25(OH) Vitamin D with SIM was calculated using 
logistic regression with adjustment for age and CK 
levels. For all statistical tests a p-Value of <0.05 was 
considered significant.
RESULTS
Between January 1, 2013 and December 31, 2013 a 
total of 825 patients (Figure 1) were tested for 25(OH) 
Vitamin D and CK at the SIH pathology laboratory. 243 
of these patients were tested concurrently. We 
identified 54 of these 243 patients to have received 
Statin therapy, 175 did not and the medical records of 
14 were not available for review. Overall 54 patients 
met the study criteria while 5 patients were excluded 
due to their co-morbidities (3 with Rheumatoid Arthritis, 
1 with Non-Hodgkin’s Lymphoma and 1 with Chronic 
Hepatitis B). 49 patients were included for final 
analysis.
Figure 1. Flow Chart of Patient Selection
The 49 patients receiving statins were divided into two 
groups based on presence or absence of 
myalgia.Differences between the two study groups were 
minimal except for age,with the mean ± standard 
deviation (SD), in the SIM and no SIM groupof 58.38 ± 
10.12 and  67.08 ± 10.04 (p = 0.01 ), respectively 
(Table 1).Analysis of the serum 25(OH) Vitamin D also 
revealed little difference between the two groups. The 
mean serum 25(OH) Vitamin D level in the 24 SIM 
patients was 17.93 ± 12.07 compared to 18.99 ± 
15.2 in the 25 no SIM group (p = 0.81). Evaluation of 
the prescribed statin, the dose and patient 
comorbidities also failed to show significance. 
DISCUSSION
Statin associated muscle adverse reports range from 
1% to 5% in controlled clinical trials to 11% to 29% in 
observational cohorts (11).This discrepancy between 
numerous studies may be due to lack of standard 
definitions that can identify statin induced muscle 
problems, making it difficult to assess the true 
percentage of theseadverse effects (11, 12). Our study 
however, showed a higher percentage (49%) of myalgia 
because we only assessed patients that were tested for 
CK instead of a random population of statin users. 
Considerable debate exists regarding the factors 
influencing occurrence of SIM, indicating a 
multifactorial etiology(13). To that effect we took into 
account patient’s age, gender, CK, specific statin used, 
dosage and co-morbiditiesalong with the 25(OH) 
Vitamin D levels.Although our analysis showsa 
significant difference in patient age betweenthe SIM 
and no SIM group (58.38 ± 10.12 and 67.08 ± 
10.04 (p = 0.01)),the mean age was higher in group 
with no myalgia, which is contrary to the effects of 
advancing age onthe development of myalgia(14).
The remaining variables showed no significant 
difference between the two study groups. Similar to the 
concern regarding factors affecting SIM, there is also 
substantial variation in the range of 25(OH) Vitamin D 
levels that are considered normal. While our laboratory 
reports a normal range of 9.5-55.5 ng/ml, the Mayo 
Medical Laboratories adopts <10ng/ml (severe 
deficiency), 10-24ng/ml (mild – moderate deficiency), 
25-80ng/ml (optimal) and >80ng/ml (possible toxicity) 
(15).Several studies have defined vitamin D deficiency 
as circulating levels of less than 80nmol (32ng/ml) 
(16). We report 21(87.5%) patients with low 25(OH) 
vitamin D (<32ng/ml)in the SIM group and 21(84%) in 
the no SIM group with an overall 42(85.71%) patients 
ascertained to be vitamin D deficient. Of these patients 
6(25%) and 9(36%) have severe 25(OH) vitamin 
deficiency (<9.5ng/ml) in the SIM and no SIM group, 
respectively. The current report revealed that the SIM 
group did not have a significantly lower vitamin D level 
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